1. Introduction
S-adenosylmethionine (SAMe) is a simple molecule, present in all living cells and synthesized in just one step by the coupling of L-methionine with the adenosyl moiety of adenosine triphosphate (ATP) [1,2]. Since its discovery by Giulio Cantoni in 1951, SAMe has been extensively studied because of its role as the main biological methyl donor, since its methyl group is easily displaced by a nucleophilic substrate to form S-adenosylhomocysteine (SAH) [3]. This review explores the role of SAMe in cancer establishment and development, as well as its potential as a biomarker and therapeutic target.Overview of S-Adenosylmethionine Synthesis
Focusing on mammals, although being synthesized in all cells, liver is the organ where most SAMe is produced, accounting for about 85% of transmethylation reactions and 50% of methionine metabolism [4,5]. SAMe is produced via the enzyme methionine adenosyltransferase (MAT) (Figure 1), which depending on the tissue, corresponds to three distinct forms: MAT I and MAT III, codified by the gene MAT1A, and MAT II, encoded by the gene MAT2A [6]. MAT1A is mainly expressed in the adult and differentiated liver [7].
The α1 subunit produced by MAT1A organizes both into dimers (MAT III) and tetramers (MAT I) [8]. MAT2A gene is expressed in extrahepatic tissues, in the fetal and proliferating liver, and in liver disease, producing the α2 subunit that adopts a tetrameric disposition (MAT II) [7,8]. Although sharing an amino acid identity of 84%, MAT II has the lowest Km for methionine (4–10 μM) whereas MAT III has the highest Km (215 μM–7 mM) and MAT I shows an intermediate Km (23 μM–1 mM). The activity of MAT enzymes is also modulated by the product of the catalytic reaction, SAMe. Normal cellular concentration of SAMe can inhibit MAT II strongly (IC50 = 60 μM), and minimally MAT I (IC50 = 400 μM) and even stimulates MAT III up to 8-fold at 500 μM SAMe [8,9,10,11]. This enzymatic diversity allows the cell to precisely regulate SAMe synthesis under variable physiological conditions, from SAMe production at low methionine levels by MAT II to the handling of very high methionine concentrations by MAT III, even avoiding possible toxicity. Likewise, inhibition by its product allows the intracellular homeostasis of SAMe.
SAMe constitutes the first product of the “methionine cycle” that interacts with the polyamine synthesis, the transsulfuration pathway and the folate cycle, in addition to participate in a wide variety of transmethylation reactions [12,13].
1.1. Importance of SAMe in Cellular Processes
Considering the wide variety of biochemical reactions in which it participates (Figure 1), as well as the numerous pathways with which it interacts, it is easy to understand the importance of SAMe for fundamental cellular processes.
1.1.1. Methylation Reactions
As mentioned above, the main and most studied function of SAMe is to participate in methylation reactions. The substrates to which SAMe is able to transfer its methyl group are varied, including DNA, RNA, proteins, small molecules or lipids, depending on the specific methyltransferase involved in the reaction.
Nucleic Acids Methylation
Through DNA methylation, which involves DNA methyltransferases (DNMTs), the methyl group of SAMe is transferred to cytosine at CpG residues modulating the access of transcription factors to chromatin and the basal transcriptional machinery. Changes in DNA methylation are crucial during processes such as genomic imprinting, embryogenesis, aging, X chromosome inactivation, and cancer [14,15,16,17].
Continuing with nucleic acids modifications, RNA methylation appears as the most common modification in the interior of mRNA, mainly mediated by methyltransferase-like protein 3 and 14 (METTL3 and METTL14) that convert adenosine to N6-methyladenosine (m6A). mRNA methylation is emerging as a key mechanism involved in translation, splicing, export and degradation, and dysregulations in the process lead to the development of various diseases, including melanoma, leukemia, pancreatic and liver cancer, etc. [18,19,20,21,22,23].
Protein Methylation
Protein methylation, both in arginine and lysine residues, promotes changes in their functionality, affecting processes such as signal transduction, ribonucleoprotein export, transcription and splicing, among others [24]. Protein arginine methyl transferases (PRMTs) constitute a family of enzymes capable of transferring SAMe methyl group to arginines, modifying them as monomethylarginines, symmetric or asymmetric dimethylarginines. Nine PRMTs have been identified, acting on a plethora of proteins corresponding to histones, signal receptors, transcription factors, coactivators, RNA-binding proteins, etc. [25]. With regard to lysine methylation, it mainly occurs on histones, components of the cellular protein synthesis machinery, mitochondrial proteins, and molecular chaperones by the action of lysine-specific methyltransferases (KTMs) resulting in mono, di, and trimethylated Lys [26,27]. Given the wide variety of biological processes affected by protein methylation, its deregulation is associated with a wide variety of diseases, including cancer.
Methylation of Small Molecules
SAMe serves as methyl donor in many biochemical methylation reactions that involve transferring its methyl group to small molecules, a process that is facilitated by specific methyltransferases. These reactions can take place in diverse organs and are fundamental to processes as SAMe and nicotinamide (NAM) homeostasis, creatine synthesis, epinephrine production, catecholamine deactivation and arsenic metabolism [28,29,30,31,32,33]. Importantly, it has been demonstrated that SAMe levels must be tightly controlled, and dysregulation of its homeostasis through lack of its catabolism by glycine N-methyltrasferase (GNMT) leads to liver disease and hepatocellular carcinoma (HCC), process that may be compensated by other methyltransferase activities such as NAM-methyltransferase (NNMT) [34,35,36,37].
Lipid Methylation
Phosphatidylcholine (PC), the major membrane phospholipid, can be synthesized from CDP-choline and phosphatidylethanolamine (PE). Particularly in the liver, both pathways act complementarily to produce the PC needed for very low-density lipoproteins (VLDL) assembly and secretion and dysregulation of PC/PE ratios can impair this process. The PE N-methyltransferase (PEMT) pathway uses SAMe to methylate PE yielding PC and being affected by both SAMe increase and depletion which ultimately can lead to dysregulation of VLDL secretion and result in liver disease, atherosclerosis and obesity [38,39,40].
1.1.2. Polyamine Synthesis
Polyamines constitute a class of low-molecular-weight molecules present in all living cells and crucial to processes involving translation, transcription, cell growth and apoptosis [41]. SAMe is decisively involved in polyamine synthesis, as the production of spermidine (SPD) and spermine (SPM) from putrescine requires the sequential addition of an aminopropyl group coming from decarboxylated SAMe (dcSAMe). In fact, the rate limiting step of polyamine synthesis consists of the decarboxylation of SAMe for producing dcSAMe, in a reaction catalyzed by the enzyme SAMe decarboxylase [13]. Since polyamines’ biological functions are related with cell growth and proliferation, gene expression, protein synthesis, membrane stability and apoptosis regulation, their relationship with a wide variety of cancers has been deeply studied [42,43,44,45,46,47].
1.1.3. Transsulfuration Pathway
Through transsulfuration pathway, the sulfur atom from SAMe (coming from dietary methionine) is transferred to serine to form cystathionine and then cysteine. Cysteine constitutes the rate-limiting precursor for glutathione (GSH) synthesis, particularly active in the liver and crucial in protecting cells by neutralizing reactive oxygen species (ROS), detoxifying xenobiotics and even regulating protein functions through S-glutathionylation [48]. The link between SAMe and transsulfuration pathway is double: first, the SAH produced after SAMe-dependent methylation reactions is converted into homocysteine (Hcy) by the enzyme S-adenosylhomocysteine hydrolase (SAHH). Hcy can enter the transsulfuration pathway transferring its sulfur to the serine in a reaction catalyzed by the enzyme cystathionine beta-synthase (CBS) and, subsequently, the enzyme cystathionase (CTH) cleaves cystathionine to form cysteine and alpha-ketobutyrate [49]. Second, SAMe exerts a regulatory function over CBS, since SAMe allosterically activates this enzyme controlling the flux towards transsulfuration pathway while reducing the remethylation of Hcy to methionine by inhibiting methylenetetrahydrofolate reductase (MTHFR) enzyme, depending on cellular excess or depletion of SAMe [13,49,50,51]. Defects in transsulfuration pathway, such as CBS deficiency, promote elevated Hcy, SAH and SAMe thereby destabilizing SAMe homeostasis, with diminished SAMe/SAH ratio, reduced GSH and lower PEMT activity which can promote the setting of mild steatotic liver disease (SLD) [52,53,54,55,56]. Moreover, it has been proposed that de novo cysteine synthesis via transsulfuration pathway can be fundamental to tumor growth in vivo when extracellular apport of cysteine is limited, demonstrating that the methylation status of the cell (SAMe/SAH ratio) can assist cancer progression under these conditions [57].
1.1.4. Folate Cycle
As described, after conversion of SAMe to SAH in transmethylation reactions and obtention of Hcy by SAHH, the Hcy that does not flux towards the transsulfuration pathway must be remethylated to methionine, therefore closing the methionine cycle. This remethylation can be mediated by two enzymes: betaine Hcy methyltransferase (BHMT), that requires betaine and is present only in liver and kidney [58], and methionine synthase (MS) that links methionine cycle with folate cycle. MS takes the methyl group from 5-methyltetrahydrofolate (5-MTHF) and transfers it to Hcy in a reaction that yields methionine and tetrahydrofolate (THF), which reacts with serine to produce 5,10-methylene-THF (5,10-CH2THF) that is again converted into 5-MTHF by the enzyme MTHFR. As commented before, the amount of Hcy that is directed to the transsulfuration pathway or is remethylated depends on the SAMe/SAH ratio since high levels of SAMe activate CBS and inhibit MTHFR whereas if the SAMe level is reduced, the remethylation gets enhanced by inactivation of CBS and activation of 5-MTHF synthesis [59,60]. Importantly, the combination of BHMT and MS activities in the liver allow the maintenance of the physiological concentration of Hcy, which is in equilibrium with SAH due to the reversibility of the SAHH enzyme. Accumulation of SAH would reduce the methylation capacity of the cell, since it is a potent inhibitor of methylation reactions [60].
2. S-Adenosylmethionine Connections with Different Types of Cancer
Given the wide range of reactions in which SAMe is involved and its numerous connections to metabolic and regulatory pathways, the role of SAMe in various diseases has been explored (Figure 2). In cancer, SAMe can influence tumor initiation, progression and treatment through multiple mechanisms. Its involvement in DNA methylation, regulation of gene expression, polyamine synthesis and redox balance, among others, plays a critical role in modulating cancer cell behavior and therapeutic responses.
SAMe depletion has been identified as a common feature of many types of cancers, including liver, colon, gastric, breast, and prostate among others [9,61,62]. This trait is often associated with changes in the epigenetic status of the cancerous cells, at different levels such as DNA and histone methylation, rRNA and tRNA methylation, chromatin remodeling and methylation-dependent regulation of non-coding RNAs. SAMe depletion decreases the methylation capacity of the cell, indicated by the SAMe/SAH ratio, producing a reduction of CpG islands methylation and global DNA hypomethylation that leads to aberrant gene expression and compromises genomic stability [63]. Regarding histone methylation, SAMe depletion has been identified to favor mono-methylation of H3K9 over di-and tri-methylation which preserves heterochromatin stability [62], but also changes in H3K4 trimethylation patterns have been identified in response to modulation of SAMe levels [64]. The methylation of rRNAs, tRNAs, miRNAs and lncRNAs are also affected by SAMe depletion producing changes in ribosome biogenesis, protein synthesis and gene regulation [65,66]. Although these mechanisms appear to be common to many types of cancer, the numerous studies conducted on the relationship between SAMe and cancer show particular mechanisms by which it may exert its influence.
2.1. Liver Cancer
As the main organ involved in SAMe synthesis and catabolism, together with the interconnections with polyamine synthesis, the transsulfuration pathway, the folate cycle and the varied methylation reactions, all essential in the liver, it is not surprising that SAMe homeostasis must be tightly controlled regardless of the different nutritional conditions or requirements of the organism. Misregulation of hepatic SAMe metabolism, particularly if chronically maintained over time, results in metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD) and defined as the presence of hepatic steatosis in conjunction with one cardiometabolic risk factor and no other discernible cause [28,34,37,67,68,69,70]. MASLD can progress from isolated hepatic steatosis (IHS) to metabolic dysfunction-associated steatohepatitis (MASH) that includes inflammation and cellular injury and, in a percentage of the cases, can progress to cirrhosis, HCC and mortality [71,72,73,74]. According to 2022 data, primary liver cancer (comprising HCC and intrahepatic cholangiocarcinoma) ranked as the sixth most frequently diagnosed cancer worldwide, and the third leading cause of cancer-related deaths after lung and colorectal cancers [75]. HCC comprises about 75–85% of primary liver cancer cases, and the trend in western countries is for MASH to overtake viral hepatitis as the leading cause of HCC [76,77,78,79]. The evidence about SAMe deficiency as a risk factor for HCC development has been recognized over years, since there is a reduction in MAT I/III activity in hepatoma cell lines, in murine HCCs, in human liver cirrhosis and HCCs and in preneoplastic and neoplastic livers [80,81].
One of the first clues implicating methionine metabolism in liver disease emerged in 1932, when Best demonstrated that a diet deficient in methyl groups (methionine, choline and folates) produced hepatic steatosis in rats [82,83]. Moreover, restriction of methionine and choline intake in mice and rats has been employed over the years as a useful animal model in the study of MASH, leading to the development of steatohepatitis, fibrosis and even HCC if sustained over time and combined with high fat diet (HFD) [84,85,86,87,88,89,90,91,92,93]. The mechanisms by which reduction of methionine and choline in the diet promote liver injury and ultimately HCC are closely linked to SAMe metabolism.
As a murine model of MASH, methionine and choline dietary restriction has been widely used over time. Traditionally, the methionine and choline deficient (MCD) diet, with total lack of both nutrients, was shown to produce steatosis, cell death, inflammation, oxidative/ER stress, and fibrosis, with severe weight loss in the absence of insulin resistance [94,95]. To avoid severe weight loss, the model was slightly modified by maintaining choline deficiency but including 0.1% methionine. This improved model, named choline-deficient L-amino acid-defined (CDAA) diet (or simply 0.1MCD), avoids weight loss but maintains similar characteristics as the MCD diet [96,97,98]. Chronic feeding with this diet results in development of adenomas and HCC related with fibrosis and oxidative DNA damage [91]. Mechanistically, feeding the 0.1MCD diet produces a reduction in SAMe hepatic concentration, together with an increase in SAH that leads to a marked decrease in SAMe/SAH ratio. This lowered methylation potential of the cell inhibits methylation reactions, including PEMT flux which impairs the synthesis of PC and, therefore, the secretion of VLDL promoting triglyceride (TG) accumulation [99]. Moreover, the first enzyme in transsulfuration pathway, CBS, is reduced after 0.1MCD diet corresponding with a diminished GSH and GSH/GSSG ratio, biomarker of oxidative stress. Hepatic TG accumulation, oxidative stress, occurrence of oxidized species of fatty acids and lipotoxicity, all of them maintained over time, are proposed to be the main promoters of HCC in this model.
For demonstrating the central importance of SAMe in MASLD, MASH and HCC progress, Mat1a knockout (KO) mice model was developed. Deletion of Mat1a gene in mice promotes chronic SAMe reduction in the liver, that leads to hepatic hyperplasia at 3 months of age, intrahepatic fat accumulation, MASH and fibrosis at 8 months and, spontaneous HCC by 18 months of age [68,69,80,100]. Similarly to MCD diet, these mice present reduced SAMe/SAH ratio, diminished PEMT flux and lower VLDL secretion, together with oxidative stress, reduced transsulfuration pathway and dyslipidemia. This model has offered crucial insights into the pathogenesis of HCC in the context of chronic SAMe deficiency. Importantly, DNA hypomethylation has been found in this animal model suggesting an epigenetic regulation, which also correlates with advanced forms of MASLD in patients [101], and may generate genomic instability throughout carcinogenic processes. This kind of alteration has been linked to numerous human HCCs during their development and, moreover, the apurinic/apyrimidinic endonuclease 1 (APEX1) that should protect cells against genomic instability, was found to be downregulated in Mat1a KO mice in a SAMe-dependent manner suggesting an important role of DNA hypomethylation in the development of HCC [100,102].
Another mechanism by which SAMe deficiency can promote HCC development in Mat1a KO mice is constituted by the increase of hepatic cancer stem cells. In the liver, oval cells constitute the stem cells, reside near the bile ducts and are normally quiescent. Under liver injury and in models of hepatocarcinogenesis, oval cells can activate and start proliferating. Interestingly, diets deficient in methyl groups have been used to induce the growth of oval cells [103,104], and Mat1a KO mice have a population of CD133+ CD49f+ oval cells with increased mitogen-activated protein kinase (MAPK) and extracellular signal regulated kinase (ERK) pathways that possess tumorigenic potential resembling cancer stem cells and were insensitive to transforming growth factor-β (TGF-β) apoptotic effect [100,105,106,107].
There is a third process involved in HCC onset in Mat1a KO mice through an ERK pathway misregulation. In particular, Mat1a KO mice show a reduced expression, both at mRNA and protein level, of the enzyme dual-specificity MAPK phosphatase (DUSP1) that inhibits ERK in liver cells [108]. Additionally, in human HCC DUSP1 abundance is directly correlated with apoptosis but inversely to proliferation index [109]. The mechanism whereby SAMe regulates DUSP1 in Mat1a KO mice is double: at the mRNA level deficiency of SAMe decreases p53 binding to DUSP1 promoter reducing its transcription, and at the protein level low SAMe amount increases DUSP1 ubiquitination and proteasomal degradation [108].
Another signaling pathway affected by Mat1a reduction is the axis serine/threonine protein kinase 11 (LKB1)/AMP-activated protein kinase (AMPK)/endothelial nitric oxide synthase (eNOS). In the liver, this cascade is activated by hepatocyte growth factor (HGF) and blocked by SAMe. Activation of AMPK promotes cytoplasmic translocation of the RNA binding protein Hu antigen R (HuR) that stabilizes mRNA of cell cycle proteins such as cyclin A2 and D1 [110,111]. Consequently, mice lacking Mat1a and chronic SAMe deficiency present a basal activation of LKB1 and AMPK, cytoplasmic HuR, cyclin D1 expression and proliferation [110]. In addition, the study of a Mat1a KO-derived HCC cell line (SAMe-D) demonstrated that LKB1 regulates Akt (protein kinase B)-mediated survival through its hyperphosphorylation and also blocks the apoptotic response through phosphorylation and retention of p53 in the cytoplasm [112].
The analysis of the phospho-proteome in Mat1a KO mice livers revealed a remarkable hyperphosphorylation of La-Related Protein 1 (LARP1), associated also with overexpression of this protein [113]. In this context of SAMe deficiency, cyclin-dependent kinase 2 (CDK2) is able to phosphorylate LARP1 in T449. LARP1 gets activated after phosphorylation, which induces translation of 5′-terminal oligopyrimidine (TOP)-containing mRNAs. Mat1a KO livers present induction of several TOP proteins, including the oncogenic proteins RPS3 and RPL18. Both LARP1 and TOP proteins are induced in human MASH and HCC [113].
So far, we have seen the effect on hepatic carcinogenesis of a reduced level of SAMe, however, as mentioned above, SAMe must be finely regulated by avoiding both its depletion and accumulation. In the liver, the enzyme GNMT is responsible for eliminating excess SAMe and maintaining a constant SAMe/SAH ratio. While a low SAMe/SAH ratio is able to inhibit methylation reactions, an abnormally high ratio can lead to aberrant methylations [13,114]. GNMT reduction has been detected in human HCC and in the liver of patients with alcohol-induced cirrhosis and infected with hepatitis C virus who are at risk of developing HCC [115,116,117]. Additionally, mild liver injury with elevated transaminases and SAMe levels has been detected in individuals harboring mutations in the GNMT genetic sequence [118,119]. In line with these findings, Gnmt KO murine model shows an increase of 35-fold in the hepatic SAMe content and a 100-fold increase in SAMe/SAH ratio. These mice spontaneously develop liver steatosis and fibrosis at 3 months of age and HCC by 8 months [37], but the mechanism involved in carcinogenesis is different from the one found in the case of Mat1a KO mouse. The supraphysiologic level of hepatic SAMe level in the Gnmt KO mice resulted in hypermethylation of the promoter regions of Ras and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) inhibitors (Ras-association domain family/tumor suppressor (RASSF) 1 and 4 and suppressor of cytokine signaling (SOCS) 1–3 and cytokine-inducible SH2-protein), resulting in decreased expression of these inhibitors and increased expression and activity of Ras and JAK/STAT pathways [37]. The activation of Ras/MEK/ERK and JAK/STAT pathways are essential for human HCC onset, and suppression of SOCS and RASSF has been proposed as the mechanism [13,120]. Additionally, the study of a cell line isolated from the tumor of Gnmt KO mice linked also the activation of the Ras pathway with an increase in LKB1/AMPK signaling [35].
MAT1A and GNMT are expressed in the adult liver and constitute markers of a healthy normal liver. Whereas a reduction in both enzymes is associated with liver injury and HCC development, an increase in the expression of MAT2A and MAT2B genes has been demonstrated. As previously described, MAT2A is mainly expressed in extrahepatic tissues, fetal liver and during processes that imply cell proliferation such as liver regeneration [6,121]. MAT2B gene codifies for a catalytic subunit that associates with MATII enzyme, is expressed in extrahepatic tissues and during liver development [122,123]. In HepG2 cells, MAT2A and MAT2B are induced by leptin which correlates with the mitogenic potential of the cells in a mechanism involving increase of polyamine synthesis and ERK, STAT and PI3K (Phosphoinositide 3-kinase) pathways activation [124,125]. MAT2A overexpression in liver and colon cancer increases tumor survival and chemo-resistance, by a mechanism involving B-cell lymphoma 2 (BCL-2) transcription, acting directly as a transcription factor that transactivates the BCL-2 promoter, and also stabilizing the BCL-2 protein [126]. Interestingly, MAT2B exists in two isoforms, V1 and V2, and MAT2B V1 acts as a NF-κB-dependent survival factor in liver cancer cells [123]. Studies of MAT2B interactome revealed both variants can interact with HuR and modulate subcellular localization of HuR, promoting its translocation to the cytosol where it stabilizes proliferation-related targets such as cyclin D1 and A [127]. In addition, both MAT2B splicing variants are able to interact with G Protein Coupled Receptor Kinase Interacting ArfGAP 1 (GIT1) recruiting and activating mitogen-activated protein kinase kinase (MEK) and ERK promoting growth and tumor formation [128], and also activating Ras/Raf [129]. MAT2B and GIT1 are frequently overexpressed in human liver and colon cancers, constituting a mechanism of growth and metastasis in these types of cancers [128].
2.2. Breast Cancer
Breast cancer is one of the most prevalent malignancies among woman worldwide, accounting 2.3 million new cases in 2022 and being the fourth leading cause of cancer-related deaths. In women, it ranks first in both cancer diagnoses and mortality [75]. The causes of breast cancer development are multiple, including environmental, genetic and epigenetic factors. Environmental risk factors include air pollution, endocrine disruptors, alcohol consumption, dietary factors, smoking and exposure to ionizing radiation [130,131,132,133,134,135,136]. Among the genetic causes, germ line mutations in the tumor suppressor genes BRCA1 and BRCA2, involved in maintaining genome integrity, are the most well-known genetic risks [137,138,139], and among epigenetic factors, aberrant DNA methylations in promoter regions and histone acetylations are involved in breast cancer development and therapeutic resistance [140,141,142,143].
As the universal biological methyl donor, the role of SAMe has been intensively studied in breast cancer, both in its involvement in carcinogenesis and resistance to chemotherapy as a therapeutic drug. Epigenomic study of breast tumors cohort revealed the existence of a general hypomethylated status across the genome, particularly in large, repetitive genomic regions [144]. However, localized hypermethylation spots appear concentrated in promoter-associated CpG islands, showing also subtype-specific patterns and the existence of cumulative effects of DNA replication on genomic methylation over time [144]. These findings can explain the different methylation status shown by the different studies on breast cancer epigenetics. Due to those variations in DNA methylation depending on breast tumor subtypes, genomic localization and DNA replication-related cumulative effects, many studies seem to be controversial, with strong differences among them.
DNA hypomethylation has been found in breast cancer cell lines such as MCF-7/DOX, the doxorubicin resistant variant of MCF-7. The hypomethylated status of the promoter regions of multidrug resistance 1 (MDR1), glutathione-S-transferase (GSTπ), O(6)-methylguanine DNA methyltransferase (MGMT), and urokinase-type plasminogen activator (uPA) genes has been proposed as the mechanism contributing to chemoresistance [145]. Importantly, treatment with SAMe is able to revert the hypomethylation status of this cell line and renders this resistant cell line to radiation-induced apoptosis [146]. Similar results were found for the uPA gene in the highly invasive MDA-231 human breast cancer cells, with low DNA methylation reversed by SAMe supplementation [147]. Contrary to these reports, an increase in SAMe levels, together with DNMT1 up-regulation in the tamoxifen-resistant breast cancer cell line TAMR-MCF-7, was reported to lead to PTEN (Phosphatase and tensin homolog) promoter methylation downregulating PTEN expression and increasing Akt phosphorylation. The inhibition of DNMT1 reduced tumoral growth capacity in this cell line [148]. In fact, DNA methylation has been described in many studies involving tamoxifen resistance, identifying two main mechanisms of resistance: downregulation of estrogen receptor α (ERα) expression and abnormal activation of the PI3K/AKT/mTOR (mammalian target of rapamycin) signaling pathway [149].
Considering the estrogen receptor, hypermethylation of the estrogen receptor 1 (ESR1) promoter by mechanisms involving zinc finger E-box-binding homeobox 1 (ZEB1) and interleukin-1β (IL-1β) reduces its transcription and, therefore, ERα protein expression which confers resistance to tamoxifen treatments [149,150,151]. In the same line, loss of ten-eleven translocation methylcytosine dioxygenase (TET) 2 demethylase promotes tamoxifen resistance by ERα downregulation [152]. TET1 and TET3 proteins also promote the demethylation of the ubiquitin C-terminal hydrolase L1 (UCHL1) promoter, leading to increased UCHL1 expression that, in turn, downregulates ERα expression [153]. Another known mechanism of tamoxifen resistance and sensitivity involves hyper and hypomethylation of estrogen response enhancers and methylation of histones enhancing transcription of ERα target genes [154,155]. Finally, methylation status of genes upstream or downstream ERα are also related to tamoxifen resistance or sensitivity, including p21, Wilms’ tumor 1 (WT1), inhibitor of differentiation 4 (ID4), N-acetyltransferase type 1 (NAT1), elongation of very long chain fatty acids-like (ELOVL2), and progesterone receptor α (PRA) [149].
Regarding the relationship between methylation and activation of the PI3K/AKT/mTOR pathway, in addition to the mentioned effect through DNMT1 and PTEN, the methylation of genes involved in that signaling pathway inhibition has been described [149]. The hypermethylation of ERBB receptor feedback inhibitor 1 (ERRFI1), paired-like homeodomain transcription factor 2 (PITX2) and downstream of kinase 7 (DOK7) promoters avoid PI3K/AKT/mTOR pathway inhibition conferring chemotherapy resistance to breast cancer. Hypomethylation of the 5′UTR of activating transcription factor-3 (ATF3) mRNA also constitutes a mechanism of radioresistance, stabilizing its mRNA and allowing ATF3 to upregulate the phosphorylation of AKT [156]. Additionally, while the trophoblast surface antigen 2 (TROP2) gene typically supports cell proliferation through the PI3K/AKT/mTOR pathway, its promoter becomes methylated and silenced in tamoxifen-resistant cells, potentially involving other pathways beyond PI3K/AKT/mTOR. Also, hypermethylation of genes upstream of the pathway are involved in acquired resistance of breast cancer [149].
Other methylation-related mechanisms involved in breast cancer include m6A-mediated epitranscriptomic regulation of the 5′UTR sequence of adenylate kinase 4 (AK4) mRNA by METTL3 through ROS increase and p38 activation conferring resistance to tamoxifen [157]. Also, the long noncoding RNA H19, upregulated in TAMR-MCF-7 cell line, inhibits SAHH, which reduces DNMT3B binding and methylation of Beclin1 activating autophagy and facilitating tamoxifen resistance [158].
As occurs in liver cancers, MAT2A expression appears increased in tamoxifen-resistant human breast cancers and in the TAMR-MCF-7 cell line, both compared with the tamoxifen-responsive versions. The mechanism by which MAT2A is overexpressed in these cells is due to the activation of NF-κB after downregulation of miR-146b, in response to PTEN reduction and Akt activation. Overexpression of MAT2A, in fact, would promote SAMe increase and PTEN promoter methylation, establishing a positive regulatory loop [159]. Also, MAT2B expression level positively correlates with cell growth and migration capacity of breast cancer cell lines and with the poor prognosis of human breast cancers [160].
Polyamines pathway is also related with breast cancer, being elevated and correlating with poor prognosis and cancer cell growth [161,162,163,164]. In polyamine synthesis, dcSAMe donates its aminopropyl group to putrescine and spermidine producing methylthioadenosine (MTA) that is rapidly cleaved to adenine and 5-methylthioribose-1-phosphate by the enzyme MTA phosphorylase (MTAP) initiating the salvage pathway that regenerates methionine [165]. MTAP is downregulated in various human cancers and appears to be deleted in many breast cancers [166]. Silencing of MTAP in a breast cancer cell line activates ornithine decarboxylase (ODC) activity elevating polyamines synthesis and promoting orthotopic xenograft tumor growth and metastasis [167].
Recently, it has been demonstrated that, in the highly aggressive basal-like breast cancer (BLBC), the SAMe decarboxylase proenzyme (AMD1) is elevated. AMD1 is the enzyme responsible for the decarboxylation of SAMe to enter in the polyamine biosynthetic pathway and in BLBC mechanisms as promoter hypomethylation, increase of the copy number of the gene and SOX10 transcriptional activity leads to its overexpression and spermidine production increase. This increased spermidine level enhances hypusination of eukaryotic initiation factor 5 A isoform 1 (eIF5A) translation factor activating transcription factor 4 (TCF4) and increasing breast cancer aggressiveness [168].
2.3. Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide, accounting for near 20% of cancer deaths. It is the first cancer for mortality and incidence for men, and the second one in woman, with smoking as the main cause and the exposure to air pollution acquiring increasing importance [75,169]. In addition to the genetic mutational changes that carcinogens promote in the lung, also changes in the inflammatory microenvironment, hypoxic stroma and epigenetic changes have been proposed as mechanisms for lung cancer onset and progression [169,170,171]. Taking this into account, SAMe involvement in lung cancer has been studied, mainly through its involvement in the epigenetic changes produced by DNMTs-mediated DNA methylation.
Whereas LKB1 behaves as a tumor oncoprotein in the liver, as mentioned earlier, it functions as a tumor suppressor in other types of cancer. In the case of lung adenocarcinomas, LKB1 loss of function has been identified associated with alterations in oncogenic pathways and mitochondrial metabolism [172]. Studies in these types of cancers have demonstrated that a large number of them present global CpG hypomethylation driven by LKB1 loss. In addition, these adenocarcinomas present decreased SAMe metabolism, repetitive element demethylation and resistance to azacytidine, a DNMT inhibitor employed as chemotherapy [173]. Authors hypothesize that depletion of SAMe is due to NNMT overexpression and overutilization of the methyl donor, which has been also observed in many cancers, including lung [174,175].
Abnormal methionine cycle has been observed in lung cancer, showing a metabolic dependence of methionine in cancer stem cells, correlating with high MAT2A expression and transmethylation rates [176]. Inhibiting MAT2A has been used to sensitize chemotherapy-resistant cells, reducing migration and proliferation and increasing apoptosis of non-small cell lung cancer due to changes in histone methylation [177]. The combination of METTL3, which is increased in non-small cell lung cancer, and MAT2A inhibitions is able to decrease m6A mRNA modification, leading to apoptosis [178,179].
Also, the SAMe-related pathways transsulfuration and polyamine have been linked to lung cancer. CBS, the first enzyme in the transsulfuration pathway, has been found highly elevated in lung adenocarcinoma in association with poor prognosis, while in lung squamous cell carcinomas the association is inverse [180]. Regarding the regulation of polyamine synthesis, ODC degradation has been shown to promote apoptosis in non-small cell lung cancer through a mechanism dependent on estrogen receptor [181]. Interestingly, inhibition of MTAP enzymatic activity in immunodeficient mice produces a systemic increase of the MTA concentration, which abrogates A549 and H358 xenograft tumor growth, cell lines derived from human non-small cell lung carcinoma and human bronchioalveolar non-small cell lung carcinoma cells lines, respectively [13,182].
SLC25A26 is the human gene encoding the mitochondrial S-adenosylmethionine carrier (mSAMC). In some cancers, including non-small cell lung cancer, its expression is inversely correlated with the survival rate of the patients. The mechanism by which SAMe transport into mitochondria can affect cancers remains unclear, with the hypothesis that it may affect SAMe cytosolic abundance and regulate methylation reactions [183,184].
2.4. Colorectal Cancer
Colorectal cancer (CRC) is a type of cancer that starts in the colon or rectum. Overall, colorectal cancer ranks in third place in terms of incidence, and second in terms of mortality, representing about 10% of the cancer cases and deaths worldwide [75]. Among the risk factors, we can find age, family history, certain genetic mutations, diet, and lifestyle factors [185]. Aberrant DNA methylations and MAT2A overexpression account for the processes affected in the disease.
DNA hypermethylation leads to gene silencing in CRC patients including epigenetic inactivation of DNA mismatch repair genes. In about 15% of CRCs, it appears a phenomenon called CpG island methylator phenotype (CIMP) characterized by substantial hypermethylation of promoter CpG island sites, resulting in the silencing of several tumor suppressor genes or other tumor-related genes [186,187]. One of the genes identified to be affected by the CIMP phenotype is MutL Homolog 1 (MLH1), part of the mismatch repair system, whose loss promotes inability to repair strand slippage within nucleotide repeats changes the size of microsatellites, increasing risk of developing CRC [188,189,190].
Conversely, global DNA hypomethylation has been detected as an early event in CRC development [191,192,193,194]. In this case, mobile genetic elements such as long interspersed nuclear element 1 (LINE-1) undergo activation, being a feature of early-onset CRC and acting as factors for increased mortality [193,194,195]. This DNA hypomethylation is linked to decreased folate and SAMe levels, which correlate with reduced SAMe/SAH ratio and, therefore, lowered methylation potential in the CRCs [193,196,197]. Low methylation of promoters in CRC has also been demonstrated for the genes c-myc and H-ras, known oncogenes, which can be reversed by SAMe treatment [198].
MAT II expression and activity along the stages of CRC has also been examined, showing that MAT II was highly expressed and active in human CRCs compared to normal tissues [199]. In the same way, MAT2A expression in human colon cancer resections, mice polyps and cell lines were increased, correlating with epidermal growth factor (EGF), insulin-like growth factor (IGF)-I and leptin-induced proliferation. Treatment with SAMe and the polyamine pathway byproduct MTA reduced MAT2A expression and blocked the mitogen-activated effects [200], even inducing apoptosis by down-regulating cellular FLICE inhibitory protein (cFLIP) [201]. Moreover, SAMe and MTA treatment is also able to inhibit CRC migration, invasion and metastasis to the liver by increasing microRNA-34a/-34c/-449a expression, in a mechanism involving Notch signaling pathway inhibition [202,203].
SAMe, through its allosteric activation of the CRC abundant CBS enzyme [180,204], has been shown to increase CRC proliferation and bioenergetics. This effect is maintained overtime following SAMe treatment at 0.1 mM in HCT116 by stimulating CBS-dependent H2S production, which acts as signaling molecule stimulating cell line proliferation and oxygen consumption rate. On the contrary, concentrations higher than 0.1 mM leads to inhibition of HCT116 proliferation after 12 h of treatment, by a CBS-independent mechanism [205]. CBS can also directly bind to cytoskeleton modulating its organization and regulating CRC cells proliferation and migration [206].
m6A mRNA methylation exerted by METTL3 plays also a role in CRC progression. METTL3 overexpression in colorectal cancers compared to normal tissue has been shown to promote methylation of JAK1 transcript and STAT3 signaling pathway activation. This mechanism increased proliferation and metastasis of cancer cells in vitro and in vivo [23].
2.5. Gastric Cancer
Stomach cancer, including cardia and noncardia gastric cancers, ranks fifth in terms of incidence and mortality globally. Helicobacter pylori infection is considered the principal cause of noncardia gastric cancer, with alcohol consumption and tobacco smoking as risk factors. For the cardia gastric cancers, obesity and gastroesophageal reflux disease are the main risk factors [75]. DNA hypomethylation of the c-myc and H-ras oncogenes, together with promoter hypermethylation of the tumor suppressor p16 has been found in gastric cancer cell lines. SAMe treatment was able to revert the hypomethylated status of c-myc and H-ras promoters slowing down tumoral cells proliferation [198]. Also, hypermethylation of DNA regions in gastric cancers is able to recruit the methyl-CpG-binding protein 2 (MeCP2), which is involved in cell proliferation and apoptosis [207,208]. The overexpression of miR-22 tumor suppressor decreases MTHFR producing a reduction in SAMe level and DNA hypermethylation, reducing MeCP2 binding and, therefore, cancer cell proliferation [209].
The activation of MAT2A expression in gastric cancer protects tumoral cells from ferroptosis, by increasing methylation of histone H3 of acyl-CoA synthetase long chain family member 3 (ACSL3) promoter in a SAMe-dependent manner [210]. Another mechanism for MAT2A-mediated gastric cancer progression involves the regulation of anti-inflammatory functions of tumor-associated monocytes. The increase in methionine cycle due to elevated MAT2A expression upregulates receptor-interacting Protein 1 (RIP1) by H3K4 methylation at the promoter region [211].
2.6. Prostate Cancer
The occurrence of prostate cancer has been related to risk factors such as advanced age and certain genetic mutations. However, environmental and lifestyle-related risk factors are not as well described in a disease that ranks second in incidence and fifth in mortality among men [75]. Mechanisms involving SAMe have been described, such as DNA and histone methylation, MAT enzymes regulation and polyamines synthesis.
Examining the global gene expression of a prostate cancer cohort it was found that, in a subset of highly aggressive tumors, expression of genes controlling SAMe synthesis associate with the expression of DNA methylation targets [14]. Hypomethylation of the promoter regions of tumor-promoting genes such as uPA and matrix metalloproteinase-2 (MMP-2) have been associated with tumor growth in prostate cancer PC-3 cell line, which can be reverted by SAMe treatment [212]. Additionally to DNA CpG methylation, in the PC-3 cell line also altered histone methylation of H3K4 and H3K27 has been described after SAMe treatment, explaining the observed changes in the expression of genes [213].
Regarding MAT enzymes regulation, miR-34a, which is under-expressed in CD44+ prostate cancer tumors [214], and also miR-34b are able to downregulate MAT2A and MAT2B protein expression by targeting their 3′UTR. Interestingly, SAMe and MTA promote miR-34a/b expression reducing MAT2A and MAT2B abundance and inhibiting cancer metastasis [202]. Similar results have been also observed for these miRNAs in pancreatic cancer [202,215].
As in many types of cancer, polyamines also play an important role in prostate cancer. In fact, it has been demonstrated that ODC overexpression can be enough to promote prostate tumorigenesis, by altering mTOR/MAPK pathway among others [216]. mTOR pathway, in addition, is able to mediate AMD1 enzyme stability in prostate cancer, thus regulating dcSAMe production and polyamines synthesis, and elevating dcSAMe/SAMe ratio in mouse and human tumoral tissue. mTORC1 inhibition produced AMD1 reduction and abrogation of tumoral cell proliferation [217]. To avoid the decrease in the SAMe pool in tumor cells that would result from activation of the polyamine pathway, the rate limiting enzyme of the salvage pathway, MTAP, appears also upregulated and is necessary for cancer growth [218].
2.7. Other Types of Cancers
SAMe implication has been demonstrated in other types of cancers, mainly through DNA and histone methylation reactions.
The H3K79 histone methylation at promoters is implicated in leukemic transformation and progression. SAMe metabolism disruption reduced cell growth and induced apoptosis [219]. Similarly, in glioblastoma, mTORC1 and mTORC2 cooperate to increase SAMe production and histone H3K27 hypermethylation, promoting tumor cell survival in cellular and animal models [220]. Conversely, glioblastoma cells treated with therapeutic doses of SAMe undergo mitotic catastrophe and death [221].
Alterations of methionine metabolism and DNA methylation capacity have been also identified in highly metastatic melanoma cell lines and osteosarcoma [222,223,224], and SAMe treatment was shown to block tumorigenesis in these kind of cancers [225,226,227].
Alterations in m6A RNA methylation status have been demonstrated in Kaposi’s sarcoma-associated herpesvirus [228]. m6A modification over MAT2A mRNA increases its expression and, therefore, SAMe abundance rendering a reduction in lytic replication, a mechanism involved in the initiation and progression of Kaposi’s sarcoma tumors [229].
Separate mention should be made of NNMT identified alterations in expression across various types of cancers. Notably, NNMT expression is upregulated in several malignancies, including kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, pancreatic adenocarcinoma, glioblastoma multiforme, sarcoma, and lymphoid neoplasm diffuse large B-cell lymphoma [29]. High levels of NNMT expression have also been reported at both mRNA and protein levels in Merkel cell carcinoma [230] and ovarian cancer [231] as a poor prognostic feature and an advantage for cancer progression. This suggests that NNMT upregulation may be a critical factor contributing to tumor progression in these cancers, potentially enhancing tumorigenic processes such as cell proliferation, migration, and chemoresistance. In contrast, in the case of oral squamous cell carcinoma there is an inverse correlation between NNMT expression level and metastasis [232]. In other cancer types, including adrenocortical carcinoma, cholangiocarcinoma, kidney chromophobe, pheochromocytoma and paraganglioma, thyroid carcinoma and skin cutaneous melanoma, NNMT expression appears to be significantly lower [29]. These findings underscore the complex and context-dependent role of NNMT in cancer biology, where its function appears to vary widely depending on the cancer type. Several NNMT inhibitors have been identified, including methylated quinolines, nicotinamide analogues, covalent inhibitors, and amino-adenosine derived bisubstrate inhibitors [233,234,235,236]. These inhibitors could serve as valuable tools for further understanding NNMT’s role in various pathologies. Moreover, the development of potent and selective NNMT inhibitors could pave the way for novel therapeutic strategies targeting cancers associated with aberrant NNMT activity.
Finally, elevated SAMe levels have also been found to increase cell growth and viability in multiple myeloma and leukemic cells. In the case of multiple myeloma, these abnormally elevated SAMe levels have been linked to high MAT2A expression, and inhibiting it leads to SAMe levels decrease and impaired cell viability and proliferation [237]. Similarly, in leukemic cells, the regulatory subunit of MAT II, MAT2B, has been proposed to be responsible for SAMe level increase and higher proliferation [238].
3. S-Adenosylmethionine as Biomarker and Therapy
Considering the central role of SAMe in methylation processes and cellular metabolism, changes in its levels and in methionine cycle-related enzymes have been proposed as diagnostic and prognostic biomarkers. In liver cancers, including HCC and cholangiocarcinoma, MAT1A expression and activity has been found to be reduced [61] correlating with depletion of SAMe levels, promoter methylation status and, also, associates with MAT2A induction [121,239]. Moreover, the expression of the regulatory subunit MAT2B is frequently linked to the increase in MAT2A, conferring growth advantage to liver cancer cells [61,121,123,240] and potentially serving as biomarkers. Furthermore, SAMe is able to modulate the levels of certain lncRNAs altered in HCC, which have been proposed as biomarkers of liver cancer progression [241]. In lung cancer, plasma level of SAMe has been proposed as early detection biomarker since it is elevated in serum of patients with cancer compared to healthy individuals [242]. Finally, promoter DNA methylation status of some particular genes is used in diagnosis and prognosis of CRC [243].
In line with the broad range of cancer types in which SAMe homeostasis is impaired, its use as in anticancer therapy has been frequently explored. This includes chemoprevention, treatment and chemosensibilization in a wide type of malignancies, including hepatic, gastric, breast and colorectal cancers, among others. Table 1 summarizes SAMe roles as biomarker and therapy.
In the case of liver cancer, the reduction in SAMe content and SAMe/SAH ratio has been frequently observed during HCC onset and development, and in hepatic stages in risk of developing HCC such as cirrhotic liver. Therefore, the effect of SAMe supplementation has been widely explored in different cellular and animal models of HCC development [13,244,245,246,247,248], including preventing or reducing the occurrence and establishment of HCC foci, showing proapoptotic effects in the tumoral cells and angiogenesis decrease. However, in the case of a previously existing HCC, SAMe treatment was not able to reduce tumor size even after 24 days of intravenous infusion [117]. The proposed mechanism by which HCC was not affected by SAMe in this model is due to compensatory induction of methyltransferases (mainly GNMT) in the normal hepatic tissue to prevent supraphysiologic accumulation of SAMe. When translating the SAMe chemopreventive effect observed in animal models into clinical trial, the results were not promising. Oral SAMe administration during 24 weeks to patients with hepatitis C cirrhosis failed to reduce the HCC marker alpha-fetoprotein (AFP) serum levels in comparison with placebo group [249]. However, there were limitations with this study, including the high dropout rate and short follow-up duration. Thus, although SAMe shows potential as an anticancer therapy for liver tumors, key aspects must be addressed before its application in clinical practice. Alternatively, strategies forcing the expression of MAT1A in liver cancer, instead of directly treating with SAMe, were shown to reduce HCC growth and angiogenesis, and increase apoptosis in in vitro and in vivo models [250].
Regarding SAMe use as chemotherapy in other types of cancer, its use has been highly studied in gastric, colorectal, breast, head and neck, osteosarcoma, lung, prostate and retinoblastoma cancers, both as single treatment and in combination with other drugs as a chemosensitizing agent. The mechanisms of action by which SAMe exerts the antitumoral effects include a plethora of processes due to its varied biological activities. In breast cancer cell lines, SAMe treatment modulates the expression of miRNA-34a, miRNA-34c and miRNA-486-5p leading to caspase-dependent apoptosis and autophagy [251], but is also able to epigenetically regulate uPA and MMP-2 genes by hypermethylation of CpG promoter sequences inhibiting cellular invasion and growth [147,252,253]. Interestingly, the treatment of breast cancer with SAMe in combination with the demethylating agent decitabine allows to target both DNA hypermethylation and hypomethylation of cancer-related pathways reducing tumor volume and lung metastasis [254]. The combination of SAMe with the widely employed drug doxorubicin in CG5, MCF-7 and MDA-MB 231 breast cancer cells enhances apoptotic cell death through Fas/FasL-dependent caspase 8 and 3 activation [255]. In the case of doxorubicin resistant cancer, SAMe treatment can sensitize tumoral cell lines to radiation-induced apoptosis by modifying global DNA hypomethylation profile [146]. Moreover, SAMe pro-apoptotic effects are potentiated by the autophagy inhibitor chloroquine [256], as the autophagy is frequently employed by cancer cells to escape chemotherapy.
The combination of cisplatin and SAMe exerts a synergistic effect on head and neck squamous cancer blocking cell proliferation and migration and increasing apoptosis through a mechanism involving ER-stress [257,258]. SAMe metabolism targeting has also been found to sensitize cisplatin-resistant cells in lung cancer to cisplatin treatment. In this case, both the inhibition of MAT2A and methionine restriction reduce histone methylation modulating apoptosis, DNA repair and tumor necrosis factor (TNF) pathway promoting cisplatin sensibilization [177]. Following this line, the joined inhibition of MTAP and MAT2A promotes lethality in tumor models of CRC by reducing SAMe availability and increasing MTA level, thus rising MTA/SAMe ratio and inhibiting PRMT5 activity [259]. Also, in p53 deleted colon cancer cells, SAMe treatment bypasses uL3 ribosomal protein-mediated drug resistance [260].
Table 1Various mechanisms of SAMe as biomarker and therapy in different types of cancers.
Type of Cancer | Type of Role | Effect/Mechanism | References |
---|---|---|---|
Liver cancer (HCC, cholangiocarcinoma) | Biomarker | Reduction in MAT1A expression and activity | [61] |
Depletion of SAMe, reduction of promoter methylation, MAT2A and MAT2B increase | [61,121,123,239,240] | ||
Biomarker lncRNAs are modulated by SAMe | [241] | ||
Prevention | SAMe supplementation reduces HCC foci occurrence and establishment (animal model) | [117] | |
Treatment | MAT1A forced expression reduces HCC growth and angiogenesis, and increases apoptosis in vitro and in vivo | [250] | |
Breast cancer | Treatment | SAMe modulates miRNA-34a, miRNA-34c and miRNA-486-5p leading to apoptosis and autophagy | [251] |
SAMe hypermethylates uPA and MMP-2 genes inhibiting cellular invasion and growth | [147,252,253] | ||
Combined therapy | SAMe + Decitabine: targets DNA hypermethylation and hypomethylation reducing reduced tumor volume and metastasis to the lung | [254] | |
SAMe + doxorubicin: enhances apoptotic cell death through Fas/FasL-dependent caspase 8 and 3 activation | [255] | ||
SAMe + chloroquine: inhibition of autophagy potentiates SAMe-induced apoptosis | [256] | ||
Sensitization | SAMe sensitizes cancer to radiation-induced apoptosis | [146] | |
Colorectal carcinoma | Biomarker | Promoter DNA methylation status serves as diagnosis and prognosis | [243] |
Treatment | MTAP and MAT2A inhibition promotes lethality in CRC blocking PRMT5 | [259] | |
Sensitization | SAMe treatment bypasses uL3-mediated drug resistance | [260] | |
Lung cancer | Biomarker | Elevated SAMe plasma level as early detection biomarker | [242] |
Sensitization | MAT2A inhibition sensitizes to cisplatin treatment | [177] | |
Head and neck squamous cancer | Combined therapy | SAMe + cisplatin: promotes ER-stress leading to apoptosis and reduced proliferation and migration | [257,258] |
Gastric cancer | Treatment | SAMe hypermethylates uPA, c-myc and H-ras inhibiting growth | [198,261] |
Glioblastoma | Treatment | SAMe induces cell cycle arrest and apoptosis and mitotic catastrophe-induced death | [221] |
Osteosarcoma and prostate | Treatment | SAMe downregulates ERK1/2 and STAT3 inducing apoptosis and blocking invasion | [226,227,262] |
Retinoblastoma | Treatment | SAMe inhibits Wnt2/β-catenin pathway reducing tumor growth | [263] |
Various | Chemoprotection | SAMe protects against chemotherapy-induced liver injury and reduces cancer-related fatigue | [264,265,266] |
In gastric cancer, SAMe is able to reverse the hypomethylated status of genes such as uPA, c-myc and H-ras inhibiting tumor growth, both in vitro and in vivo [198,261]. Recently, it has been also demonstrated that SAMe treatment of glioblastoma cells induces cell cycle arrest and apoptosis, together with downregulation of DNA repair mechanisms promoting mitotic catastrophe-induced death [221]. The very aggressive and highly metastatic tumor osteosarcoma shows induction of apoptosis and blocking of invasion after SAMe treatment, by downregulation of ERK1/2 and STAT3 pathways [226,227] as also happens in prostate cancer cells [262]. The Wnt2/β-catenin pathway, activated in many types of cancers and playing a significant role in its progression, is also inhibited in response to SAMe treatment in retinoblastoma showing tumor growth reduction in a xenograft animal model [263].
Finally, SAMe supplementation has been proven beneficial for reducing chemotherapy-induced side effects. In the case of drug-induced liver injury (DILI), the levels of the liver damage markers alanine transaminase (ALT), aspartate transaminase (AST) and lactate dehydrogenase (LDH) were reduced after SAMe supplementation in patients under chemotherapy treatment [264], and in resected CRC patients treated with adjuvant FOLFOX regimen, in which also reduced cancer-related fatigue [265,266].
SAMe has shown promising results in improving the efficacy of numerous chemotherapies and in various types of cancer. Advances in the study of this type of therapy, particularly in combination with other chemotherapeutics, could lead to improvements in the management of the treatment of diverse malignancies.
4. Conclusions and Future Perspectives
SAMe, as the main biological methyl donor, plays a central role in cellular processes such as DNA, RNA, and protein methylation, as well as metabolic pathways like polyamine synthesis and the transsulfuration cycle. These diverse functions establish its importance in cancer development and progression. Since SAMe discovery more than 70 years ago, extensive research has clarified SAMe’s biological roles, particularly its involvement in methylation and metabolism and its dysregulation in cancer. SAMe depletion has been identified as a hallmark of many cancers, and enzymes involved in its metabolism have been identified as tumor biomarkers [9,61]. Altered MAT1A, MAT2A and MAT2B expression, as well as SAMe/SAH ratio, potentially provide diagnostic and prognostic insights.
SAMe’s relationship with cancer has been explored in a plethora of cancers, both investigating its implication in cancer establishment and progression and as a potential therapeutic agent. Despite the wide variety of malignancies studied, many of the works just employ tumoral cell lines but lack validation of the results in preclinical animal models. Moreover, several of the animal experiments have been performed using xenograft models by injecting the previously in vitro tested tumor cell lines into immunocompromised mice [254,259,261]. Although these kinds of animal models are very useful, the validation of discoveries and treatments in preclinical animal models developing the specific type of cancer studied may more reliably resemble the pathology that occurs in humans and would be more closed to the clinical findings.
Regarding therapeutic strategies involving SAMe supplementation, overexpression or inhibition of methionine cycle enzymes (MAT1A, MAT2A) [177,250,259] and synergistic therapies with chemotherapeutic agents have shown significant promise in preclinical studies. Moreover, SAMe-based treatments have demonstrated potential in restoring methylation homeostasis, overcoming chemoresistance, and enhancing apoptosis in various cancers, including HCC, CRC and breast cancer. However, translating these preclinical successes into effective clinical applications remains challenging due to variability in SAMe’s effects, delivery issues and a lack of tailored patient stratification. This absence of precise biomarkers to obtain patient subtyping avoids the effective transfer of treatments from the bench to the bedside, as demonstrated by the few clinical trials conducted and the low success achieved [249]. In addition, there are other points that should be addressed for the obtention of an effective SAMe treatment, including the inefficient delivery of SAMe due to low bioavailability and the paradoxical outcomes that can be obtained (e.g., excessive methylation) derived from context-dependent effects.
Always keeping in mind those limitations, the most promising emerging area would be the targeting of methionine cycle enzymes to regulate SAMe availability in cancers that exhibit methionine dependency, such as CRC and lung cancer [177,259]. Similarly, exploring epitranscriptomic regulation (e.g., m6A modifications) mediated by SAMe and its interaction with non-coding RNAs opens new opportunities for understanding tumor progression and resistance mechanisms [157,241]. Precision medicine approaches focusing on individual tumor profiles and integrating SAMe-targeted strategies with chemotherapeutics would increase the effectiveness of cancerous treatments. In our opinion, combination therapies taking advantage of SAMe’s ability to enhance chemosensitivity and modulate epigenetic status will be the most promising, as SAMe combined with decitabine or doxorubicin in targeting breast cancer, with cisplatin in head and neck squamous cancer, or even sensitizing cancer cells to radiotherapy [146,254,255,257,258].
In summary, the modulation of SAMe metabolism broadly found in many kinds of different cancers makes it a potential target for therapy, mainly in combination with other chemotherapeutics as a sensitizing agent. Nevertheless, important concerns regarding among others precision or personalized medicine approaches must be addressed before using it in clinical practice, improving therapeutic outcomes across a broad range of malignancies.
Conceptualization, D.F.-R. and J.M.M.; writing—original draft preparation, D.F.-R. and F.L.-O.; writing—review and editing, D.F.-R., F.L.-O., S.C.L. and J.M.M.; supervision, S.C.L. and J.M.M.; project administration, S.C.L. and J.M.M.; funding acquisition, S.C.L. and J.M.M. All authors have read and agreed to the published version of the manuscript.
The authors declare no conflicts of interest.
5-MTHF | 5-methyltetrahydrofolate |
5,10-CH2THF | 5,10-methylene-THF |
TOP | 5′-terminal oligopyrimidine |
ACSL3 | acyl-CoA synthetase long chain family member 3 |
AFP | alpha-fetoprotein |
AK4 | adenylate kinase 4 |
AKT | protein kinase B |
ALT | alanine transaminase |
AMD | SAMe decarboxylase proenzyme |
AMD1 | SAMe decarboxylase proenzyme 1 |
AMPK | AMP-activated protein kinase |
APEX1 | apurinic/apyrimidinic endonuclease 1 |
AST | aspartate transaminase |
ATF3 | activating transcription factor-3 |
ATP | adenosine triphosphate |
BHMT | betaine Hcy methyltransferase |
CBS | cystathionine beta-synthase |
CDAA | choline-deficient L-amino acid-defined |
CDK2 | cyclin-dependent kinase 2 |
cFLIP | cellular FLICE inhibitory protein |
CIMP | CpG island methylator phenotype |
CRC | colorectal cancer |
CTH | cystathionase |
dcSAMe | decarboxylated SAMe |
DILI | drug-induced liver injury |
DNMTs | DNA methyltransferases |
DNMT1 | DNA methyltransferase 1 |
DOK7 | downstream of kinase 7 |
DUSP1 | dual-specificity MAPK phosphatase |
EGF | epidermal growth factor |
eIF5A | eukaryotic initiation factor 5 A isoform 1 |
ELOVL2 | elongation of very long chain fatty acids-like |
eNOS | endothelial nitric oxide synthase |
ERα | estrogen receptor α |
ERK | extracellular signal regulated kinase |
ERRFI1 | ERBB receptor feedback inhibitor 1 |
ESR1 | estrogen receptor 1 |
GIT1 | G Protein Coupled Receptor Kinase Interacting ArfGAP 1 |
GNMT | glycine N-methyltrasferase |
GSH | glutathione |
GSTπ | glutathione-S-transferase |
H3K4 | histone H3 fourth lysine |
H3K27 | histone H3 27th lysine |
H-Ras | HRas proto-oncogene |
HCC | hepatocellular carcinoma |
HFD | high fat diet |
HGF | hepatocyte growth factor |
HuR | Hu antigen R |
ID4 | inhibitor of differentiation 4 |
IGF | insulin-like growth factor |
IL-1β | interleukin-1β |
IHS | isolated hepatic steatosis |
JAK | Janus kinase |
KTMs | lysine-specific methyltransferases |
LARP1 | La-Related Protein 1 |
LDH | lactate dehydrogenase |
LINE-1 | long interspersed nuclear element 1 |
LKB1 | serine/threonine protein kinase 11 |
m6A | N6-methyladenosine |
MAPK | mitogen-activated protein kinase |
MASH | metabolic disfunction-associated steatohepatitis |
MASLD | metabolic disfunction-associated steatotic liver disease |
MAT | methionine adenosyltransferase |
MAT I/III | methionine Adenosyltransferase I/III |
MAT1A | methionine adenosyltransferase 1A |
MAT2A | methionine adenosyltransferase 2A |
MAT2B | methionine adenosyltransferase 2 non-catalytic beta subunit |
MCD | methionine and choline deficient |
MDR1 | multidrug resistance 1 |
MeCP2 | methyl-CpG-binding protein 2 |
MEK | mitogen-activated protein kinase kinase |
METTL3 | methyltransferase-like protein 3 |
METTL14 | methyltransferase-like protein 14 |
MGMT | O(6)-methylguanine DNA methyltransferase |
MMP-2 | matrix metalloproteinase-2 |
MS | methionine synthase |
mSAMC | mitochondrial S-adenosylmethionine carrier |
MTs | methyltransferases |
MTA | methylthioadenosine |
MTAP | MTA phosphorylase |
MTHFR | methylenetetrahydrofolate reductase |
mTOR | Mammalian target of rapamycin |
MLH1 | MutL Homolog 1 |
NAFLD | non-alcoholic fatty liver disease |
NAM | nicotinamide |
NAT1 | N-acetyltransferase type 1 |
NNMT | nicotinamide methyltransferase |
ODC | ornithine decarboxylase |
PC | phosphatidylcholine |
PE | phosphatidylethanolamine |
PEMT | phosphatidylethanolamine N-methyltransferase |
PI3K | Phosphoinositide 3-kinase |
PITX2 | paired-like homeodomain transcription factor 2 |
PRA | progesterone receptor α |
PRMTs | protein arginine methyl transferases |
PTEN | Phosphatase and tensin homolog |
RASSF | Ras-association domain family/tumor suppressor |
RIP1 | receptor-interacting Protein 1 |
ROS | reactive oxygen species |
SAH | S-adenosylhomocysteine |
SAHH | S-adenosylhomocysteine hydrolase |
SAMe | S-adenosylmethionine |
SLD | steatotic liver disease |
SOCS | suppressor of cytokine signaling |
SPD | spermidine |
SPM | spermine |
STAT | signal transducer and activator of transcription |
TCF4 | transcription factor 4 |
TET | translocation methylcytosine dioxygenase |
TG | triglyceride |
TGF-β | transforming growth factor-β |
THF | tetrahydrofolate |
TNF | tumor necrosis factor |
TROP2 | trophoblast surface antigen 2 |
UCHL1 | ubiquitin C-terminal hydrolase L1 |
uPA | urokinase-type plasminogen activator |
VLDL | very low density lipoproteins |
WT1 | Wilms’ tumor 1 |
ZEB1 | zinc finger E-box-binding homeobox 1 |
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Figure 1. Overview of the methionine cycle, and connections with folate cycle, and transsulfuration pathway illustrating the role of SAMe in key cellular processes including nucleic acids, protein and lipid methylation, SAMe/SAH homeostasis and polyamine synthesis. SAMe molecule structure obtained from: https://3d.nih.gov/doi/11913/2 (accessed on 16 December 2024). Gray: carbon; blue: nitrogen; red: oxygen; yellow: sulfur; white: hydrogen. ADO: adenosine; AMD: adenosylmethionine decarboxylase; BHMT: betaine HCYmethyltransferase; CBS: cystathionine beta-synthase; CTH: cystathionase; DNMTs: DNA methyltransferases; GNMT: glycine N-methyltrasferase; GSH: glutathione; KTMs: lysine-specific methyltransferases; MAT: methionine adenosyltransferase; METTL3/14: methyltransferase-like protein 3/14; MS: methionine synthase; MTs: methyltransferases; MTHFR: methylenetetrahydrofolate reductase; NNMT: nicotinamide N-methyltransferase; PC: phosphatidylcholine; PE: phosphatidylethanolamine; PEMT: phosphatidylethanolamine N-methyltransferase; PRMTs: protein arginine methyl transferases; SAH: S-adenosylhomocysteine; SAHH: S-adenosylhomocysteine hydrolase; SAMe: S-adenosylmethionine.
Figure 2. Role of S-Adenosylmethionine in various cancers. The figure highlights tissue-specific changes in SAMe metabolism, DNA methylation patterns, and the expression of key enzymes in cancers of the prostate, lung, liver, breast, colorectal, gastric, and other tissues. SAMe molecule structure obtained from: https://3d.nih.gov/doi/11913/2 (accessed on 16 December 2024). Gray: carbon; blue: nitrogen; red: oxygen; yellow: sulfur; white: hydrogen. ACSL3: acyl-CoA synthetase long chain family member 3; AK4: Adenylate kinase 4; AKT: Protein kinase B; AMD: SAMe decarboxylase proenzyme; AMD1: SAMe decarboxylase proenzyme 1; AMPK: AMP-activated protein kinase; ATF3: Activating transcription factor 3; CBS: Cystathionine beta-synthase; CIMP: CpG island methylator phenotype; DNMT1: DNA (cytosine-5)-methyltransferase 1; DOK7: Downstream of kinase 7; DUSP1: Dual-specificity MAPK phosphatase; ERα: Estrogen receptor α; ERK: Extracellular signal regulated kinase; ERRFI1: ERBB receptor feedback inhibitor 1; GIT1: G Protein Coupled Receptor Kinase Interacting ArfGAP 1; GNMT: Glycine N-methyltrasferase; GSTπ: Glutathione-S-transferase; H3K4: 4th lysine in Histone H3; H3K27: 27th lysine in Histone H3; HCC: Hepatocellular carcinoma; H-Ras: HRas proto-oncogene; JAK: Janus kinase; LARP1: La-Related Protein 1; LINE-1: Long interspersed nuclear element 1; LKB1: Serine/threonine protein kinase 11; m6A: N6-methyladenosine; MAT I/III: Methionine Adenosyltransferase I/III; MAT1A: Methionine Adenosyltransferase 1A; MAT2A: Methionine Adenosyltransferase 2A; MAT2B: Methionine Adenosyltransferase 2 Non-Catalytic Beta Subunit; MCD: Methionine and choline deficient; MDR1: Multidrug resistance 1; MeCP2:methyl-CpG-binding protein 2; METTL3: Methyltransferase-like protein 3; MGMT: O(6)-methylguanine DNA methyltransferase; MLH1: MutL Homolog 1; MMP-2: Matrix metalloproteinase-2; mSAMC: Mitochondrial S-adenosylmethionine carrier; MTAP: MTA phosphorylase; mTOR: Mammalian target of rapamycin; NNMT: Nicotinamide methyltransferase; ODC: Ornithine decarboxylase; PI3K: Phosphoinositide 3-kinase; PITX2: Paired like homeodomain transcription factor 2; PTEN: Phosphatase and tensin homolog; RIP1: receptor-interacting Protein 1; SAMe: S-adenosylmethionine; STAT3: Signal transducer and activator of transcription; uPA: Urokinase-type plasminogen activator.
References
1. Cantoni, G.L. S-Adenosylmethionine; a New Intermediate Formed Enzymatically from L-Methionine and Adenosinetriphosphate. J. Biol. Chem.; 1953; 204, pp. 403-416. [DOI: https://dx.doi.org/10.1016/S0021-9258(18)66148-4] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/13084611]
2. Cantoni, G.L. Activation of Methionine for Transmethylation. J. Biol. Chem.; 1951; 189, pp. 745-754. [DOI: https://dx.doi.org/10.1016/S0021-9258(18)44891-0] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14832292]
3. Bridwell-Rabb, J.; Grell, T.A.J.; Drennan, C.L. A Rich Man, Poor Man Story of S-Adenosylmethionine and Cobalamin Revisited. Annu. Rev. Biochem.; 2018; 87, pp. 555-584. [DOI: https://dx.doi.org/10.1146/annurev-biochem-062917-012500] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29925255]
4. Finkelstein, J.D. Methionine Metabolism in Mammals. J. Nutr. Biochem.; 1990; 1, pp. 228-237. [DOI: https://dx.doi.org/10.1016/0955-2863(90)90070-2]
5. Mudd, S.H.; Poole, J.R. Labile Methyl Balances for Normal Humans on Various Dietary Regimens. Metabolism; 1975; 24, pp. 721-735. [DOI: https://dx.doi.org/10.1016/0026-0495(75)90040-2]
6. Mato, J.M.; Corrales, F.J.; Lu, S.C.; Avila, M.A. S-Adenosylmethionine: A Control Switch That Regulates Liver Function. FASEB J.; 2002; 16, pp. 15-26. [DOI: https://dx.doi.org/10.1096/fj.01-0401rev]
7. Gil, B.; Casado, M.; Pajares, M.A.; Bosca, L.; Mato, J.M.; Martin-Sanz, P.; Alvarez, L. Differential Expression Pattern of S-Adenosylmethionine Synthetase Isoenzymes during Rat Liver Development. Hepatology; 1996; 24, pp. 876-881. [DOI: https://dx.doi.org/10.1002/hep.510240420]
8. Kotb, M.; Mudd, S.H.; Mato, J.M.; Geller, A.M.; Kredich, N.M.; Chou, J.Y.; Cantoni, G.L. Consensus Nomenclature for the Mammalian Methionine Adenosyltransferase Genes and Gene Products. Trends Genet.; 1997; 13, pp. 51-52. [DOI: https://dx.doi.org/10.1016/S0168-9525(97)01013-5]
9. Lu, S.C.; Mato, J.M. Role of Methionine Adenosyltransferase and S-Adenosylmethionine in Alcohol-Associated Liver Cancer. Alcohol.; 2005; 35, pp. 227-234. [DOI: https://dx.doi.org/10.1016/j.alcohol.2005.03.011]
10. Cabrero, C.; Puerta, J.; Metabolismo, S.A.; Hormonas, N.Y.; Diaz, J. Purification and Comparison of Two Forms of S-Adenosyl-l-Methionine Synthetase from Rat Liver. Eur. J. Biochem.; 1987; 170, pp. 299-304. [DOI: https://dx.doi.org/10.1111/j.1432-1033.1987.tb13699.x]
11. Sullivan, D.M.; Hoffman, J.L. Fractionation and Kinetic Properties of Rat Liver and Kidney Methionine Adenosyltransferase Isozymes. Biochemistry; 1983; 22, pp. 1636-1641. [DOI: https://dx.doi.org/10.1021/bi00276a017]
12. Pascale, R.M.; Simile, M.M.; Calvisi, D.F.; Feo, C.F.; Feo, F. S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. Cells; 2022; 11, 409. [DOI: https://dx.doi.org/10.3390/cells11030409]
13. Lu, S.C.; Mato, J.M. S-Adenosylmethionine in Liver Health, Injury, and Cancer. Physiol. Rev.; 2012; 92, pp. 1515-1542. [DOI: https://dx.doi.org/10.1152/physrev.00047.2011] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23073625]
14. Long, M.D.; Smiraglia, D.J.; Campbell, M.J. The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. Biomolecules; 2017; 7, 15. [DOI: https://dx.doi.org/10.3390/biom7010015]
15. Jones, M.J.; Goodman, S.J.; Kobor, M.S. DNA Methylation and Healthy Human Aging. Aging Cell; 2015; 14, pp. 924-932. [DOI: https://dx.doi.org/10.1111/acel.12349]
16. Nicuiescu, M.D.; Lupu, D.S. Nutritional Influence on Epigenetics and Effects on Longevity. Curr. Opin. Clin. Nutr. Metab. Care; 2011; 14, pp. 35-40. [DOI: https://dx.doi.org/10.1097/MCO.0b013e328340ff7c] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21088573]
17. Esteller, M. Cancer Epigenomics: DNA Methylomes and Histone-Modification Maps. Nat. Rev. Genet.; 2007; 8, pp. 286-298. [DOI: https://dx.doi.org/10.1038/nrg2005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17339880]
18. Zaccara, S.; Ries, R.J.; Jaffrey, S.R. Reading, Writing and Erasing MRNA Methylation. Nat. Rev. Mol. Cell Biol.; 2019; 20, pp. 608-624. [DOI: https://dx.doi.org/10.1038/s41580-019-0168-5]
19. Shi, H.; Wei, J.; He, C. Where, When and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol. Cell; 2019; 74, 640. [DOI: https://dx.doi.org/10.1016/j.molcel.2019.04.025]
20. Ianniello, Z.; Fatica, A. N6-Methyladenosine Role in Acute Myeloid Leukaemia. Int. J. Mol. Sci.; 2018; 19, 2345. [DOI: https://dx.doi.org/10.3390/ijms19082345]
21. Deng, X.; Su, R.; Weng, H.; Huang, H.; Li, Z.; Chen, J. RNA N6-Methyladenosine Modification in Cancers: Current Status and Perspectives. Cell Res.; 2018; 28, 507. [DOI: https://dx.doi.org/10.1038/s41422-018-0034-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29686311]
22. Chen, X.Y.; Zhang, J.; Zhu, J.S. The Role of M6A RNA Methylation in Human Cancer. Mol. Cancer; 2019; 18, 103. [DOI: https://dx.doi.org/10.1186/s12943-019-1033-z] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31142332]
23. Sun, Y.; Gong, W.; Zhang, S. METTL3 Promotes Colorectal Cancer Progression through Activating JAK1/STAT3 Signaling Pathway. Cell Death Dis.; 2023; 14, 765. [DOI: https://dx.doi.org/10.1038/s41419-023-06287-w] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38001065]
24. Grillo, M.A.; Colombatto, S. S-Adenosylmethionine and Protein Methylation. Amino Acids; 2005; 28, pp. 357-362. [DOI: https://dx.doi.org/10.1007/s00726-005-0197-6]
25. Hwang, J.W.; Cho, Y.; Bae, G.U.; Kim, S.N.; Kim, Y.K. Protein Arginine Methyltransferases: Promising Targets for Cancer Therapy. Exp. Mol. Med.; 2021; 53, pp. 788-808. [DOI: https://dx.doi.org/10.1038/s12276-021-00613-y]
26. Falnes, P.; Jakobsson, M.E.; Davydova, E.; Ho, A.; Malecki, J. Protein Lysine Methylation by Seven-β-Strand Methyltransferases. Biochem. J.; 2016; 473, pp. 1995-2009. [DOI: https://dx.doi.org/10.1042/BCJ20160117]
27. Falnes, P.; Małecki, J.M.; Herrera, M.C.; Bengtsen, M.; Davydova, E. Human Seven-β-Strand (METTL) Methyltransferases—Conquering the Universe of Protein Lysine Methylation. J. Biol. Chem.; 2023; 299, 104661. [DOI: https://dx.doi.org/10.1016/j.jbc.2023.104661]
28. Luka, Z.; Mudd, S.H.; Wagner, C. Glycine N-Methyltransferase and Regulation of S-Adenosylmethionine Levels. J. Biol. Chem.; 2009; 284, pp. 22507-22511. [DOI: https://dx.doi.org/10.1074/jbc.R109.019273]
29. Wang, W.; Yang, C.; Wang, T.; Deng, H. Complex Roles of Nicotinamide N-Methyltransferase in Cancer Progression. Cell Death Dis.; 2022; 13, 267. [DOI: https://dx.doi.org/10.1038/s41419-022-04713-z]
30. Da Silva, R.P.; Nissim, I.; Brosnan, M.E.; Brosnan, J.T. Creatine Synthesis: Hepatic Metabolism of Guanidinoacetate and Creatine in the Rat in Vitro and in Vivo. Am. J. Physiol. Endocrinol. Metab.; 2009; 296, E256. [DOI: https://dx.doi.org/10.1152/ajpendo.90547.2008]
31. Drinkwater, N.; Gee, C.L.; Puri, M.; Criscione, K.R.; McLeish, M.J.; Grunewald, G.L.; Martin, J.L. Molecular Recognition of Physiological Substrate Noradrenaline by the Adrenaline Synthesising Enzyme PNMT and Factors Influencing Its Methyltransferase Activity. Biochem. J.; 2009; 422, 463. [DOI: https://dx.doi.org/10.1042/BJ20090702]
32. Li, J.; Sun, C.; Cai, W.; Li, J.; Rosen, B.P.; Chen, J. Insights into S-Adenosyl-l-Methionine (SAM)-Dependent Methyltransferase Related Diseases and Genetic Polymorphisms. Mutat. Res. Rev. Mutat. Res.; 2021; 788, 108396. [DOI: https://dx.doi.org/10.1016/j.mrrev.2021.108396] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34893161]
33. Drobna, Z.; Styblo, M.; Thomas, D.J. An Overview of Arsenic Metabolism and Toxicity. Curr. Protoc. Toxicol.; 2009; 42, pp. 4.31.1-4.31.6. [DOI: https://dx.doi.org/10.1002/0471140856.tx0431s42] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25419261]
34. Varela-Rey, M.; Fernández-Ramos, D.; Martínez-López, N.; Embade, N.; Gómez-Santos, L.; Beraza, N.; Vázquez-Chantada, M.; Rodríguez, J.; Luka, Z.; Wagner, C. et al. Impaired Liver Regeneration in Mice Lacking Glycine N-Methyltransferase. Hepatology; 2009; 50, pp. 443-452. [DOI: https://dx.doi.org/10.1002/hep.23033]
35. Martínez–López, N.; García–Rodríguez, J.L.; Varela–Rey, M.; Gutiérrez, V.; Fernández–Ramos, D.; Beraza, N.; Aransay, A.M.; Schlangen, K.; Lozano, J.J.; Aspichueta, P. et al. Hepatoma Cells From Mice Deficient in Glycine N-Methyltransferase Have Increased RAS Signaling and Activation of Liver Kinase B1. Gastroenterology; 2012; 143, pp. 787-798.e13. [DOI: https://dx.doi.org/10.1053/j.gastro.2012.05.050]
36. Varela-Rey, M.; Martínez-López, N.; Fernández-Ramos, D.; Embade, N.; Calvisi, D.F.; Woodhoo, A.; Rodríguez, J.; Fraga, M.F.; Julve, J.; Rodríguez-Millán, E. et al. Fatty Liver and Fibrosis in Glycine N-Methyltransferase Knockout Mice Is Prevented by Nicotinamide. Hepatology; 2010; 52, pp. 105-114. [DOI: https://dx.doi.org/10.1002/hep.23639]
37. Martínez-Chantar, M.L.; Vázquez-Chantada, M.; Ariz, U.; Martínez, N.; Varela, M.; Luka, Z.; Capdevila, A.; Rodríguez, J.; Aransay, A.M.; Matthiesen, R. et al. Loss of the Glycine N-Methyltransferase Gene Leads to Steatosis and Hepatocellular Carcinoma in Mice. Hepatology; 2008; 47, pp. 1191-1199. [DOI: https://dx.doi.org/10.1002/hep.22159]
38. Vance, D.E. Phospholipid Methylation in Mammals: From Biochemistry to Physiological Function. Biochim. Et Biophys. Acta BBA Biomembr.; 2014; 1838, pp. 1477-1487. [DOI: https://dx.doi.org/10.1016/j.bbamem.2013.10.018]
39. van der Veen, J.N.; Kennelly, J.P.; Wan, S.; Vance, J.E.; Vance, D.E.; Jacobs, R.L. The Critical Role of Phosphatidylcholine and Phosphatidylethanolamine Metabolism in Health and Disease. Biochim. Biophys. Acta Biomembr.; 2017; 1859, pp. 1558-1572. [DOI: https://dx.doi.org/10.1016/j.bbamem.2017.04.006]
40. Martínez-Uña, M.; Varela-Rey, M.; Cano, A.; Fernández-Ares, L.; Beraza, N.; Aurrekoetxea, I.; Martínez-Arranz, I.; García-Rodríguez, J.L.; Buqué, X.; Mestre, D. et al. Excess S-Adenosylmethionine Reroutes Phosphatidylethanolamine towards Phosphatidylcholine and Triglyceride Synthesis. Hepatology; 2013; 58, pp. 1296-1305. [DOI: https://dx.doi.org/10.1002/hep.26399]
41. Perez-Leal, O.; Merali, S. Regulation of Polyamine Metabolism by Translational Control. Amino Acids; 2012; 42, pp. 611-617. [DOI: https://dx.doi.org/10.1007/s00726-011-1036-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21811825]
42. Pegg, A.E. Mammalian Polyamine Metabolism and Function. IUBMB Life; 2009; 61, pp. 880-894. [DOI: https://dx.doi.org/10.1002/iub.230] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19603518]
43. Casero, R.A.; Marton, L.J. Targeting Polyamine Metabolism and Function in Cancer and Other Hyperproliferative Diseases. Nat. Rev. Drug Discov.; 2007; 6, pp. 373-390. [DOI: https://dx.doi.org/10.1038/nrd2243] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17464296]
44. Childs, A.C.; Mehta, D.J.; Gerner, E.W. Polyamine-Dependent Gene Expression. Cell Mol. Life Sci.; 2003; 60, 1394. [DOI: https://dx.doi.org/10.1007/s00018-003-2332-4]
45. Igarashi, K.; Kashiwagi, K. Modulation of Cellular Function by Polyamines. Int. J. Biochem. Cell Biol.; 2010; 42, pp. 39-51. [DOI: https://dx.doi.org/10.1016/j.biocel.2009.07.009]
46. Schuber, F. Influence of Polyamines on Membrane Functions. Biochem. J.; 1989; 260, pp. 1-10. [DOI: https://dx.doi.org/10.1042/bj2600001]
47. Seiler, N.; Raul, F. Polyamines and Apoptosis. J. Cell Mol. Med.; 2005; 9, pp. 623-642. [DOI: https://dx.doi.org/10.1111/j.1582-4934.2005.tb00493.x]
48. Pompella, A.; Visvikis, A.; Paolicchi, A.; De Tata, V.; Casini, A.F. The Changing Faces of Glutathione, a Cellular Protagonist. Biochem. Pharmacol.; 2003; 66, pp. 1499-1503. [DOI: https://dx.doi.org/10.1016/S0006-2952(03)00504-5]
49. Zhang, H.F.; Klein Geltink, R.I.; Parker, S.J.; Sorensen, P.H. Transsulfuration, Minor Player or Critical for Cysteine Homeostasis in Cancer. Trends Cell Biol.; 2022; 32, 800. [DOI: https://dx.doi.org/10.1016/j.tcb.2022.02.009]
50. Zuhra, K.; Augsburger, F.; Majtan, T.; Szabo, C. Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition. Biomolecules; 2020; 10, 697. [DOI: https://dx.doi.org/10.3390/biom10050697]
51. Prudova, A.; Bauman, Z.; Braun, A.; Vitvitsky, V.; Lu, S.C.; Banerjee, R. S-Adenosylmethionine Stabilizes Cystathionine Beta-Synthase and Modulates Redox Capacity. Proc. Natl. Acad. Sci. USA; 2006; 103, pp. 6489-6494. [DOI: https://dx.doi.org/10.1073/pnas.0509531103] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16614071]
52. Jacobs, R.L.; Jiang, H.; Kennelly, J.P.; Orlicky, D.J.; Allen, R.H.; Stabler, S.P.; Maclean, K.N. Cystathionine Beta-Synthase Deficiency Alters Hepatic Phospholipid and Choline Metabolism: Post-Translational Repression of Phosphatidylethanolamine N-Methyltransferase Is a Consequence Rather than a Cause of Liver Injury in Homocystinuria. Mol. Genet. Metab.; 2017; 120, pp. 325-336. [DOI: https://dx.doi.org/10.1016/j.ymgme.2017.02.010] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28291718]
53. Choumenkovitch, S.F.; Selhub, J.; Bagley, P.J.; Maeda, N.; Nadeau, M.R.; Smith, D.E.; Choi, S.W. In the Cystathionine Beta-Synthase Knockout Mouse, Elevations in Total Plasma Homocysteine Increase Tissue S-Adenosylhomocysteine, but Responses of S-Adenosylmethionine and DNA Methylation Are Tissue Specific. J. Nutr.; 2002; 132, pp. 2157-2160. [DOI: https://dx.doi.org/10.1093/jn/132.8.2157] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12163655]
54. Kruger, W.D. Cystathionine β-Synthase Deficiency: Of Mice and Men. Mol. Genet. Metab.; 2017; 121, pp. 199-205. [DOI: https://dx.doi.org/10.1016/j.ymgme.2017.05.011]
55. Harvey Mudd, S.; Finkelstein, J.D.; Irreverre, F.; Laster, L. Homocystinuria: An Enzymatic Defect. Science; 1964; 143, pp. 1443-1445. [DOI: https://dx.doi.org/10.1126/science.143.3613.1443]
56. Serpa, J. Cysteine as a Carbon Source, a Hot Spot in Cancer Cells Survival. Front. Oncol.; 2020; 10, 533316. [DOI: https://dx.doi.org/10.3389/fonc.2020.00947]
57. Zhu, J.; Berisa, M.; Schwörer, S.; Qin, W.; Cross, J.R.; Thompson, C.B. Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation. Cell Metab.; 2019; 30, pp. 865-876.e5. [DOI: https://dx.doi.org/10.1016/j.cmet.2019.09.009]
58. Pajares, M.A.; Pérez-Sala, D. Betaine Homocysteine S-Methyltransferase: Just a Regulator of Homocysteine Metabolism?. Cell. Mol. Life Sci.; 2006; 63, pp. 2792-2803. [DOI: https://dx.doi.org/10.1007/s00018-006-6249-6]
59. Ducker, G.S.; Rabinowitz, J.D. Cell Metabolism Review One-Carbon Metabolism in Health and Disease. Cell Metab.; 2017; 25, pp. 27-42. [DOI: https://dx.doi.org/10.1016/j.cmet.2016.08.009]
60. Fernández-Ramos, D.; Lopitz-Otsoa, F.; Millet, O.; Alonso, C.; Lu, S.C.; Mato, J.M. One Carbon Metabolism and S-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes. Livers; 2022; 2, pp. 243-257. [DOI: https://dx.doi.org/10.3390/livers2040020]
61. Maldonado, L.Y.; Arsene, D.; Mato, J.M.; Lu, S.C. Methionine Adenosyltransferases in Cancers: Mechanisms of Dysregulation and Implications for Therapy. Exp. Biol. Med.; 2018; 243, pp. 107-117. [DOI: https://dx.doi.org/10.1177/1535370217740860] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29141455]
62. Haws, S.A.; Yu, D.; Ye, C.; Wille, C.K.; Nguyen, L.C.; Krautkramer, K.A.; Tomasiewicz, J.L.; Yang, S.E.; Miller, B.R.; Liu, W.H. et al. Methyl-Metabolite Depletion Elicits Adaptive Responses to Support Heterochromatin Stability and Epigenetic Persistence. Mol. Cell; 2020; 78, pp. 210-223.e8. [DOI: https://dx.doi.org/10.1016/j.molcel.2020.03.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32208170]
63. Caudill, M.A.; Wang, J.C.; Melnyk, S.; Pogribny, I.P.; Jernigan, S.; Collins, M.D.; Santos-Guzman, J.; Swendseid, M.E.; Cogger, E.A.; James, S.J. Intracellular S-Adenosylhomocysteine Concentrations Predict Global DNA Hypomethylation in Tissues of Methyl-Deficient Cystathionine β-Synthase Heterozygous Mice. J. Nutr.; 2001; 131, pp. 2811-2818. [DOI: https://dx.doi.org/10.1093/jn/131.11.2811] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11694601]
64. Ding, W.; Smulan, L.J.; Hou, N.S.; Taubert, S.; Watts, J.L.; Walker, A.K. S-Adenosylmethionine Levels Govern Innate Immunity through Distinct Methylation-Dependent Pathways. Cell Metab.; 2015; 22, pp. 633-645. [DOI: https://dx.doi.org/10.1016/j.cmet.2015.07.013] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26321661]
65. Mosca, L.; Vitiello, F.; Borzacchiello, L.; Coppola, A.; Tranchese, R.V.; Pagano, M.; Caraglia, M.; Cacciapuoti, G.; Porcelli, M. Mutual Correlation between Non-Coding RNA and S-Adenosylmethionine in Human Cancer: Roles and Therapeutic Opportunities. Cancers; 2021; 13, 3264. [DOI: https://dx.doi.org/10.3390/cancers13133264]
66. Ishiguro, K.; Arai, T.; Suzuki, T. Depletion of S-Adenosylmethionine Impacts on Ribosome Biogenesis through Hypomodification of a Single RRNA Methylation. Nucleic Acids Res.; 2019; 47, pp. 4226-4239. [DOI: https://dx.doi.org/10.1093/nar/gkz111]
67. Rinella, M.E.; Lazarus, J.V.; Ratziu, V.; Francque, S.M.; Sanyal, A.J.; Kanwal, F.; Romero, D.; Abdelmalek, M.F.; Anstee, Q.M.; Arab, J.P. et al. A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. J. Hepatol.; 2023; 79, pp. 1542-1556. [DOI: https://dx.doi.org/10.1016/j.jhep.2023.06.003]
68. Alonso, C.; Fernández-Ramos, D.; Varela-Rey, M.; Martínez-Arranz, I.; Navasa, N.; Van Liempd, S.M.; Lavín Trueba, J.L.; Mayo, R.; Ilisso, C.P.; de Juan, V.G. et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology; 2017; 152, pp. 1449-1461.e7. [DOI: https://dx.doi.org/10.1053/j.gastro.2017.01.015]
69. Lu, S.C.; Alvarez, L.; Huang, Z.-Z.; Chen, L.; An, W.; Corrales, F.J.; Avila, M.A.; Kanel, G.; Mato, J.M. Methionine Adenosyltransferase 1A Knockout Mice Are Predisposed to Liver Injury and Exhibit Increased Expression of Genes Involved in Proliferation. Proc. Natl. Acad. Sci. USA; 2001; 98, pp. 5560-5565. [DOI: https://dx.doi.org/10.1073/pnas.091016398]
70. Rinella, M.E.; Lazarus, J.V.; Ratziu, V.; Francque, S.M.; Sanyal, A.J.; Kanwal, F.; Romero, D.; Abdelmalek, M.F.; Anstee, Q.M.; Arab, J.P. et al. A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. Hepatology; 2023; 78, 1966. [DOI: https://dx.doi.org/10.1097/HEP.0000000000000520]
71. Noureddin, M.; Mato, J.M.; Lu, S.C. Nonalcoholic Fatty Liver Disease: Update on Pathogenesis, Diagnosis, Treatment and the Role of S-Adenosylmethionine. Exp. Biol. Med.; 2015; 240, pp. 809-820. [DOI: https://dx.doi.org/10.1177/1535370215579161] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25873078]
72. Williams, C.D.; Stengel, J.; Asike, M.I.; Torres, D.M.; Shaw, J.; Contreras, M.; Landt, C.L.; Harrison, S.A. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. Gastroenterology; 2011; 140, pp. 124-131. [DOI: https://dx.doi.org/10.1053/j.gastro.2010.09.038] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20858492]
73. Labrecque, D.R.; Abbas, Z.; Anania, F.; Ferenci, P.; Khan, A.G.; Goh, K.L.; Hamid, S.S.; Isakov, V.; Lizarzabal, M.; Peñaranda, M.M. et al. World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. J. Clin. Gastroenterol.; 2014; 48, pp. 467-473. [DOI: https://dx.doi.org/10.1097/MCG.0000000000000116] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24921212]
74. Takuma, Y.; Nouso, K. Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma: Our Case Series and Literature Review. World J. Gastroenterol. WJG; 2010; 16, 1436. [DOI: https://dx.doi.org/10.3748/wjg.v16.i12.1436]
75. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.; 2024; 74, pp. 229-263. [DOI: https://dx.doi.org/10.3322/caac.21834]
76. Hester, D.; Golabi, P.; Paik, J.; Younossi, I.; Mishra, A.; Younossi, Z.M. Among Medicare Patients With Hepatocellular Carcinoma, Non-Alcoholic Fatty Liver Disease Is the Most Common Etiology and Cause of Mortality. J. Clin. Gastroenterol.; 2020; 54, pp. 459-467. [DOI: https://dx.doi.org/10.1097/MCG.0000000000001172]
77. Younossi, Z.; Stepanova, M.; Ong, J.P.; Jacobson, I.M.; Bugianesi, E.; Duseja, A.; Eguchi, Y.; Wong, V.W.; Negro, F.; Yilmaz, Y. et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin. Gastroenterol. Hepatol.; 2019; 17, pp. 748-755.e3. [DOI: https://dx.doi.org/10.1016/j.cgh.2018.05.057]
78. Wong, R.J.; Cheung, R.; Ahmed, A. Nonalcoholic Steatohepatitis Is the Most Rapidly Growing Indication for Liver Transplantation in Patients with Hepatocellular Carcinoma in the U.S. Hepatology; 2014; 59, pp. 2188-2195. [DOI: https://dx.doi.org/10.1002/hep.26986]
79. Ahmad, M.I.; Khan, M.U.; Kodali, S.; Shetty, A.; Bell, S.M.; Victor, D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. J. Hepatocell. Carcinoma; 2022; 9, 477. [DOI: https://dx.doi.org/10.2147/JHC.S344559]
80. Martínez-Chantar, M.L.; Corrales, F.J.; Martínez-Cruz, L.A.; García-Trevijano, E.R.; Huang, Z.-Z.; Chen, L.; Kanel, G.; Avila, M.A.; Mato, J.M.; Lu, S.C. Spontaneous Oxidative Stress and Liver Tumors in Mice Lacking Methionine Adenosyltransferase 1A. FASEB J.; 2002; 16, pp. 1292-1294. [DOI: https://dx.doi.org/10.1096/fj.02-0078fje]
81. Cai, J.; Sun, W.M.; Hwang, J.J.; Stain, S.C.; Lu, S.C. Changes in S-Adenosylmethionine Synthetase in Human Liver Cancer: Molecular Characterization and Significance. Hepatology; 1996; 24, pp. 1090-1097. [DOI: https://dx.doi.org/10.1053/jhep.1996.v24.pm0008903381] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8903381]
82. Best, C.H.; Huntsman, M.E. The Effects of the Components of Lecithine upon Deposition of Fat in the Liver. J. Physiol.; 1932; 75, pp. 405-412. [DOI: https://dx.doi.org/10.1113/jphysiol.1932.sp002899] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16994325]
83. Best, C.H.; Hershey, J.M.; Huntsman, M.E. The Effect of Lecithine on Fat Deposition in the Liver of the Normal Rat. J. Physiol.; 1932; 75, pp. 56-66. [DOI: https://dx.doi.org/10.1113/jphysiol.1932.sp002875] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16994301]
84. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.-X.; Diehl, A.M. Inhibiting Triglyceride Synthesis Improves Hepatic Steatosis but Exacerbates Liver Damage and Fibrosis in Obese Mice with Nonalcoholic Steatohepatitis. Hepatology; 2007; 45, pp. 1366-1374. [DOI: https://dx.doi.org/10.1002/hep.21655]
85. Yamaguchi, K.; Itoh, Y.; Yokomizo, C.; Nishimura, T.; Niimi, T.; Fujii, H.; Okanoue, T.; Yoshikawa, T. Blockade of Interleukin-6 Signaling Enhances Hepatic Steatosis but Improves Liver Injury in Methionine Choline-Deficient Diet-Fed Mice. Lab. Investig.; 2010; 90, pp. 1169-1178. [DOI: https://dx.doi.org/10.1038/labinvest.2010.75]
86. Montandon, S.A.; Somm, E.; Loizides-Mangold, U.; de Vito, C.; Dibner, C.; Jornayvaz, F.R. Multi-Technique Comparison of Atherogenic and MCD NASH Models Highlights Changes in Sphingolipid Metabolism. Sci. Rep.; 2019; 9, 16810. [DOI: https://dx.doi.org/10.1038/s41598-019-53346-4]
87. Rizki, G.; Arnaboldi, L.; Gabrielli, B.; Yan, J.; Lee, G.S.; Ng, R.K.; Turner, S.M.; Badger, T.M.; Pitas, R.E.; Maher, J.J. Mice Fed a Lipogenic Methionine-Choline-Deficient Diet Develop Hypermetabolism Coincident with Hepatic Suppression of SCD-1. J. Lipid Res.; 2006; 47, pp. 2280-2290. [DOI: https://dx.doi.org/10.1194/jlr.M600198-JLR200]
88. Park, H.S.; Jeon, B.H.; Woo, S.H.; Leem, J.; Jang, J.E.; Cho, M.S.; Park, I.S.; Lee, K.U.; Koh, E.H. Time-Dependent Changes in Lipid Metabolism in Mice with Methionine Choline Deficiency-Induced Fatty Liver Disease. Mol. Cells; 2011; 32, pp. 571-577. [DOI: https://dx.doi.org/10.1007/s10059-011-0184-6]
89. Wolf, M.J.; Adili, A.; Piotrowitz, K.; Abdullah, Z.; Boege, Y.; Stemmer, K.; Ringelhan, M.; Simonavicius, N.; Le Egger, M.; Wohlleber, D. et al. Cancer Cell Metabolic Activation of Intrahepatic CD8 + T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes Cancer Cell CD8 + and NKT Cells Promote NASH and NASH-Induced HCC. Cancer Cell; 2014; 26, pp. 549-564. [DOI: https://dx.doi.org/10.1016/j.ccell.2014.09.003]
90. Ikawa-Yoshida, A.; Matsuo, S.; Kato, A.; Ohmori, Y.; Higashida, A.; Kaneko, E.; Matsumoto, M. Hepatocellular Carcinoma in a Mouse Model Fed a Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet. Int. J. Exp. Pathol.; 2017; 98, pp. 221-233. [DOI: https://dx.doi.org/10.1111/iep.12240]
91. Denda, A.; Kitayama, W.; Kishida, H.; Murata, N.; Tamura, K.; Kusuoka, O.; Tsutsumi, M.; Nishikawa, F.; Kita, E.; Nakae, D. et al. Expression of Inducible Nitric Oxide (NO) Synthase but Not Prevention by Its Gene Ablation of Hepatocarcinogenesis with Fibrosis Caused by a Choline-Deficient, l-Amino Acid-Defined Diet in Rats and Mice. Nitric Oxide; 2007; 16, pp. 164-176. [DOI: https://dx.doi.org/10.1016/j.niox.2006.07.002] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16931074]
92. Matsumoto, M.; Hada, N.; Sakamaki, Y.; Uno, A.; Shiga, T.; Tanaka, C.; Ito, T.; Katsume, A.; Sudoh, M. An Improved Mouse Model That Rapidly Develops Fibrosis in Non-Alcoholic Steatohepatitis. Int. J. Exp. Pathol.; 2013; 94, 93. [DOI: https://dx.doi.org/10.1111/iep.12008] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23305254]
93. Rinella, M.E.; Elias, M.S.; Smolak, R.R.; Fu, T.; Borensztajn, J.; Green, R.M. Mechanisms of Hepatic Steatosis in Mice Fed a Lipogenic Methionine Choline-Deficient Diet. J. Lipid Res.; 2008; 49, pp. 1068-1076. [DOI: https://dx.doi.org/10.1194/jlr.M800042-JLR200] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18227531]
94. Gallage, S.; Avila, J.E.B.; Ramadori, P.; Focaccia, E.; Rahbari, M.; Ali, A.; Malek, N.P.; Anstee, Q.M.; Heikenwalder, M. A Researcher’s Guide to Preclinical Mouse NASH Models. Nat. Metab.; 2022; 4, pp. 1632-1649. [DOI: https://dx.doi.org/10.1038/s42255-022-00700-y]
95. Itagaki, H.; Shimizu, K.; Morikawa, S.; Ogawa, K.; Ezaki, T. Morphological and Functional Characterization of Non-Alcoholic Fatty Liver Disease Induced by a Methionine-Choline-Deficient Diet in C57BL/6 Mice. Int. J. Clin. Exp. Pathol.; 2013; 6, pp. 2683-2696.
96. Kucsera, D.; Tóth, V.E.; Gergő, D.; Vörös, I.; Onódi, Z.; Görbe, A.; Ferdinandy, P.; Varga, Z.V. Characterization of the CDAA Diet-Induced Non-Alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice. Front. Physiol.; 2021; 12, 609465. [DOI: https://dx.doi.org/10.3389/fphys.2021.609465]
97. Kodama, Y.; Kisseleva, T.; Iwaisako, K.; Miura, K.; Taura, K.; De Minicis, S.; Österreicher, C.H.; Schnabl, B.; Seki, E.; Brenner, D.A. C-Jun N-Terminal Kinase-1 From Hematopoietic Cells Mediates Progression From Hepatic Steatosis to Steatohepatitis and Fibrosis in Mice. Gastroenterology; 2009; 137, pp. 1467-1477.e5. [DOI: https://dx.doi.org/10.1053/j.gastro.2009.06.045]
98. Yoshiji, H.; Nakae, D.; Mizumoto, Y.; Horiguchi, K.; Tamura, K.; Denda, A.; Tsujii, T.; Konishi, Y. Inhibitory Effect of Dietary Iron Deficiency on Inductions of Putative Preneoplastic Lesions as Well as 8-Hydroxydeoxyguanosine in DNA and Lipid Peroxidation in the Livers of Rats Caused by Exposure to a Choline-Deficient L-Amino Acid Defined Diet. Carcinogenesis; 1992; 13, pp. 1227-1233. [DOI: https://dx.doi.org/10.1093/carcin/13.7.1227]
99. Iruarrizaga-Lejarreta, M.; Varela-Rey, M.; Fernández-Ramos, D.; Martínez-Arranz, I.; Delgado, T.C.; Simon, J.; Gutiérrez-de Juan, V.; delaCruz-Villar, L.; Azkargorta, M.; Lavin, J.L. et al. Role of Aramchol in Steatohepatitis and Fibrosis in Mice. Hepatol. Commun.; 2017; 1, pp. 911-927. [DOI: https://dx.doi.org/10.1002/hep4.1107]
100. Ramani, K.; Mato, J.M.; Lu, S.C. Role of Methionine Adenosyltransferase Genes in Hepatocarcinogenesis. Cancers; 2011; 3, pp. 1480-1497. [DOI: https://dx.doi.org/10.3390/cancers3021480]
101. Murphy, S.K.; Yang, H.; Moylan, C.A.; Pang, H.; Dellinger, A.; Abdelmalek, M.F.; Garrett, M.E.; Ashley–Koch, A.; Suzuki, A.; Tillmann, H.L. et al. Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology; 2013; 145, pp. 1076-1087. [DOI: https://dx.doi.org/10.1053/j.gastro.2013.07.047]
102. Calvisi, D.F.; Simile, M.M.; Ladu, S.; Pellegrino, R.; De Murtas, V.; Pinna, F.; Tomasi, M.L.; Frau, M.; Virdis, P.; De Miglio, M.R. et al. Altered Methionine Metabolism and Global DNA Methylation in Liver Cancer: Relationship with Genomic Instability and Prognosis. Int. J. Cancer; 2007; 121, pp. 2410-2420. [DOI: https://dx.doi.org/10.1002/ijc.22940] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17680562]
103. Jelnes, P.; Santoni-Rugiu, E.; Rasmussen, M.; Friis, S.L.; Nielsen, J.H.; Tygstrup, N.; Bisgaard, H.C. Remarkable Heterogeneity Displayed by Oval Cells in Rat and Mouse Models of Stem Cell–Mediated Liver Regeneration. Hepatology; 2007; 45, pp. 1462-1470. [DOI: https://dx.doi.org/10.1002/hep.21569] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17538966]
104. Dumble, M.L.; Croager, E.J.; Yeoh, G.C.T.; Quail, E.A. Generation and Characterization of P53 Null Transformed Hepatic Progenitor Cells: Oval Cells Give Rise to Hepatocellular Carcinoma. Carcinogenesis; 2002; 23, pp. 435-445. [DOI: https://dx.doi.org/10.1093/carcin/23.3.435]
105. Nguyen, L.N.; Furuya, M.H.; Wolfraim, L.A.; Nguyen, A.P.; Holdren, M.S.; Campbell, J.S.; Knight, B.; Yeoh, G.C.T.; Fausto, N.; Parks, W.T. Transforming Growth Factor-Beta Differentially Regulates Oval Cell and Hepatocyte Proliferation. Hepatology; 2007; 45, pp. 31-41. [DOI: https://dx.doi.org/10.1002/hep.21466] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17187411]
106. Ding, W.; Mouzaki, M.; You, H.; Laird, J.C.; Mato, J.; Lu, S.C.; Rountree, C.B. CD133+ Liver Cancer Stem Cells from Methionine Adenosyl Transferase 1A–Deficient Mice Demonstrate Resistance to Transforming Growth Factor (TGF)-β–Induced Apoptosis. Hepatology; 2009; 49, pp. 1277-1286. [DOI: https://dx.doi.org/10.1002/hep.22743] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19115422]
107. Rountree, C.B.; Senadheera, S.; Mato, J.M.; Crooks, G.M.; Lu, S.C. Expansion of Liver Cancer Stem Cells during Aging in Methionine Adenosyltransferase 1A–Deficient Mice. Hepatology; 2008; 47, pp. 1288-1297. [DOI: https://dx.doi.org/10.1002/hep.22141]
108. Tomasi, M.L.; Ramani, K.; Lopitz-Otsoa, F.; Rodríguez, M.S.; Li, T.W.H.; Ko, K.; Yang, H.; Bardag-Gorce, F.; Iglesias-Ara, A.; Feo, F. et al. S-Adenosylmethionine Regulates Dual-Specificity Mitogen-Activated Protein Kinase Phosphatase Expression in Mouse and Human Hepatocytes. Hepatology; 2010; 51, pp. 2152-2161. [DOI: https://dx.doi.org/10.1002/hep.23530]
109. Calvisi, D.F.; Pinna, F.; Meloni, F.; Ladu, S.; Pellegrino, R.; Sini, M.; Daino, L.; Simile, M.M.; De Miglio, M.R.; Virdis, P. et al. Dual-Specificity Phosphatase 1 Ubiquitination in Extracellular Signal-Regulated Kinase–Mediated Control of Growth in Human Hepatocellular Carcinoma. Cancer Res.; 2008; 68, pp. 4192-4200. [DOI: https://dx.doi.org/10.1158/0008-5472.CAN-07-6157]
110. Vázquez-Chantada, M.; Ariz, U.; Varela-Rey, M.; Embade, N.; Martínez-Lopez, N.; Fernández-Ramos, D.; Gómez-Santos, L.; Lamas, S.; Lu, S.C.; Martínez-Chantar, M.L. et al. Evidence for LKB1/AMP-Activated Protein Kinase/Endothelial Nitric Oxide Synthase Cascade Regulated by Hepatocyte Growth Factor, S-Adenosylmethionine, and Nitric Oxide in Hepatocyte Proliferation. Hepatology; 2009; 49, pp. 608-617. [DOI: https://dx.doi.org/10.1002/hep.22660]
111. Martínez-Chantar, M.L.; Vázquez-Chantada, M.; Garnacho, M.; Latasa, M.U.; Varela-Rey, M.; Dotor, J.; Santamaria, M.; Martínez-Cruz, L.A.; Parada, L.A.; Lu, S.C. et al. S-Adenosylmethionine Regulates Cytoplasmic HuR via AMP-Activated Kinase. Gastroenterology; 2006; 131, pp. 223-232. [DOI: https://dx.doi.org/10.1053/j.gastro.2006.04.019] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16831604]
112. Martínez-López, N.; Varela-Rey, M.; Fernández-Ramos, D.; Woodhoo, A.; Vázquez-Chantada, M.; Embade, N.; Espinosa-Hevia, L.; Bustamante, F.J.; Parada, L.A.; Rodriguez, M.S. et al. Activation of LKB1-Akt Pathway Independent of Phosphoinositide 3-Kinase Plays a Critical Role in the Proliferation of Hepatocellular Carcinoma from Nonalcoholic Steatohepatitis. Hepatology; 2010; 52, pp. 1621-1631. [DOI: https://dx.doi.org/10.1002/hep.23860] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20815019]
113. Ramani, K.; Robinson, A.E.; Berlind, J.; Fan, W.; Abeynayake, A.; Binek, A.; Barbier-Torres, L.; Noureddin, M.; Nissen, N.N.; Yildirim, Z. et al. S-Adenosylmethionine Inhibits La Ribonucleoprotein Domain Family Member 1 in Murine Liver and Human Liver Cancer Cells. Hepatology; 2021; 75, 280. [DOI: https://dx.doi.org/10.1002/hep.32130] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34449924]
114. Mudd, S.H.; Brosnan, J.T.; Brosnan, M.E.; Jacobs, R.L.; Stabler, S.P.; Allen, R.H.; Vance, D.E.; Wagner, C. Methyl Balance and Transmethylation Fluxes in Humans. Am. J. Clin. Nutr.; 2007; 85, pp. 19-25. [DOI: https://dx.doi.org/10.1093/ajcn/85.1.19]
115. Chen, Y.M.A.; Shiu, J.Y.A.; Tzeng, S.J.; Shih, L.S.; Chen, Y.J.; Lut, W.Y.; Chen, P.H. Characterization of Glycine-N-Methyltransferase-Gene Expression in Human Hepatocellular Carcinoma. Int. J. Cancer; 1998; 75, pp. 787-793. [DOI: https://dx.doi.org/10.1002/(SICI)1097-0215(19980302)75:5<787::AID-IJC20>3.0.CO;2-2]
116. Avila, M.A.; Berasain, C.; Torres, L.; Martín-Duce, A.; Corrales, F.J.; Yang, H.; Prieto, J.; Lu, S.C.; Caballería, J.; Rodés, J. et al. Reduced MRNA Abundance of the Main Enzymes Involved in Methionine Metabolism in Human Liver Cirrhosis and Hepatocellular Carcinoma. J. Hepatol.; 2000; 33, pp. 907-914. [DOI: https://dx.doi.org/10.1016/S0168-8278(00)80122-1]
117. Lu, S.C.; Ramani, K.; Ou, X.; Lin, M.; Yu, V.; Ko, K.; Park, R.; Bottiglieri, T.; Tsukamoto, H.; Kanel, G. et al. S-Adenosylmethionine in the Chemoprevention and Treatment of Hepatocellular Carcinoma in a Rat Model. Hepatology; 2009; 50, pp. 462-471. [DOI: https://dx.doi.org/10.1002/hep.22990]
118. Mudd, S.H.; Cerone, R.; Schiaffino, M.C.; Fantasia, A.R.; Minniti, G.; Caruso, U.; Lorini, R.; Watkins, D.; Matiaszuk, N.; Rosenblatt, D.S. et al. Glycine N-methyltransferase Deficiency: A Novel Inborn Error Causing Persistent Isolated Hypermethioninaemia. J. Inherit. Metab. Dis.; 2001; 24, pp. 448-464. [DOI: https://dx.doi.org/10.1023/A:1010577512912]
119. Augoustides-Savvopoulou, P.; Luka, Z.; Karyda, S.; Stabler, S.P.; Allen, R.H.; Patsiaoura, K.; Wagner, C.; Mudd, S.H. Glycine N-Methyltransferase Deficiency: A New Patient with a Novel Mutation. J. Inherit. Metab. Dis.; 2003; 26, pp. 745-759. [DOI: https://dx.doi.org/10.1023/B:BOLI.0000009978.17777.33]
120. Calvisi, D.F.; Ladu, S.; Gorden, A.; Farina, M.; Conner, E.A.; Lee, J.S.; Factor, V.M.; Thorgeirsson, S.S. Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC. Gastroenterology; 2006; 130, pp. 1117-1128. [DOI: https://dx.doi.org/10.1053/j.gastro.2006.01.006]
121. Cai, J.; Mao, Z.; Hwang, J.J.; Lu, S.C. Differential Expression of Methionine Adenosyltransferase Genes Influences the Rate of Growth of Human Hepatocellular Carcinoma Cells. Cancer Res.; 1998; 58, pp. 1444-1450. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9537246]
122. LeGros, H.L.; Halim, A.-B.; Geller, A.M.; Kotb, M. Cloning, Expression, and Functional Characterization of the β Regulatory Subunit of Human Methionine Adenosyltransferase (MAT II). J. Biol. Chem.; 2000; 275, pp. 2359-2366. [DOI: https://dx.doi.org/10.1074/jbc.275.4.2359] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10644686]
123. Yang, H.; Ara, A.I.; Magilnick, N.; Xia, M.; Ramani, K.; Chen, H.; Lee, T.D.; Mato, J.M.; Lu, S.C. Expression Pattern, Regulation, and Functions of Methionine Adenosyltransferase 2β Splicing Variants in Hepatoma Cells. Gastroenterology; 2008; 134, pp. 281-291. [DOI: https://dx.doi.org/10.1053/j.gastro.2007.10.027] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18045590]
124. Ramani, K.; Yang, H.; Xia, M.; Ara, A.I.; Mato, J.M.; Lu, S.C. Leptin’s Mitogenic Effect in Human Liver Cancer Cells Requires Induction of Both Methionine Adenosyltransferase 2A and 2β. Hepatology; 2008; 47, pp. 521-531. [DOI: https://dx.doi.org/10.1002/hep.22064]
125. Tomasi, M.L.; Ryoo, M.; Skay, A.; Tomasi, I.; Giordano, P.; Mato, J.M.; Lu, S.C. Polyamine and Methionine Adenosyltransferase 2A Crosstalk in Human Colon and Liver Cancer. Exp. Cell Res.; 2013; 319, pp. 1902-1911. [DOI: https://dx.doi.org/10.1016/j.yexcr.2013.04.005]
126. Tomasi, M.L.; Ryoo, M.; Ramani, K.; Tomasi, I.; Giordano, P.; Mato, J.M.; Lu, S.C.; Lauda Tomasi, M.; Ryoo, M.; Ramani, K. et al. Methionine Adenosyltransferase A2 Sumoylation Positively Regulate Bcl-2 Expression in Human Colon and Liver Cancer Cells. Oncotarget; 2015; 6, pp. 37706-37723. [DOI: https://dx.doi.org/10.18632/oncotarget.5342]
127. Xia, M.; Chen, Y.; Wang, L.-C.; Zandi, E.; Yang, H.; Bemanian, S.; Martínez-Chantar, M.L.; Mato, J.M.; Lu, S.C. Novel Function and Intracellular Localization of Methionine Adenosyltransferase 2β Splicing Variants. J. Biol. Chem.; 2010; 285, pp. 20015-20021. [DOI: https://dx.doi.org/10.1074/jbc.M109.094821]
128. Peng, H.; Dara, L.; Li, T.W.H.; Zheng, Y.; Yang, H.; Tomasi, L.M.; Tomasi, I.; Giordano, P.; Mato, J.M.; Lu, S.C. Methionine Adenosyltransferase 2B-GIT1 Interplay Activates MEK1-ERK1/2 to Induce Growth in Human Liver and Colon Cancer. Hepatology; 2013; 57, pp. 2299-2313. [DOI: https://dx.doi.org/10.1002/hep.26258]
129. Peng, H.; Li, T.W.H.; Yang, H.; Moyer, M.P.; Mato, J.M.; Lu, S.C. Methionine Adenosyltransferase 2B–GIT1 Complex Serves as a Scaffold to Regulate Ras/Raf/MEK1/2 Activity in Human Liver and Colon Cancer Cells. Am. J. Pathol.; 2015; 185, pp. 1135-1144. [DOI: https://dx.doi.org/10.1016/j.ajpath.2014.12.016]
130. Segovia-Mendoza, M.; Gómez de León, C.T.; García-Becerra, R.; Ambrosio, J.; Nava-Castro, K.E.; Morales-Montor, J. The Chemical Environmental Pollutants BPA and BPS Induce Alterations of the Proteomic Profile of Different Phenotypes of Human Breast Cancer Cells: A Proposed Interactome. Environ. Res.; 2020; 191, 109960. [DOI: https://dx.doi.org/10.1016/j.envres.2020.109960]
131. Koual, M.; Tomkiewicz, C.; Cano-Sancho, G.; Antignac, J.P.; Bats, A.S.; Coumoul, X. Environmental Chemicals, Breast Cancer Progression and Drug Resistance. Environ. Health; 2020; 19, pp. 1-25. [DOI: https://dx.doi.org/10.1186/s12940-020-00670-2] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33203443]
132. Hvidtfeldt, U.A.; Chen, J.; Rodopoulou, S.; Strak, M.; de Hoogh, K.; Andersen, Z.J.; Bellander, T.; Brandt, J.; Fecht, D.; Forastiere, F. et al. Breast Cancer Incidence in Relation to Long-Term Low-Level Exposure to Air Pollution in the ELAPSE Pooled Cohort. Cancer Epidemiol. Biomark. Prev.; 2023; 32, pp. 105-113. [DOI: https://dx.doi.org/10.1158/1055-9965.EPI-22-0720] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36215200]
133. Coyle, Y.M. The Effect of Environment on Breast Cancer Risk. Breast Cancer Res. Treat.; 2004; 84, pp. 273-288. [DOI: https://dx.doi.org/10.1023/B:BREA.0000019964.33963.09] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15026625]
134. Brody, J.G.; Rudel, R.A. Environmental Pollutants and Breast Cancer. Environ. Health Perspect.; 2003; 111, pp. 1007-1019. [DOI: https://dx.doi.org/10.1289/ehp.6310]
135. Wolff, M.S.; Weston, A. Breast Cancer Risk and Environmental Exposures. Environ. Health Perspect.; 1997; 105, pp. 891-896. [DOI: https://dx.doi.org/10.1289/EHP.97105S4891]
136. Laden, F.; Hunter, D.J. ENVIRONMENTAL RISK FACTORS AND FEMALE BREAST CANCER. Annu. Rev. Public Health; 1998; 19, pp. 101-123. [DOI: https://dx.doi.org/10.1146/annurev.publhealth.19.1.101]
137. O’Donovan, P.J.; Livingston, D.M. BRCA1 and BRCA2: Breast/Ovarian Cancer Susceptibility Gene Products and Participants in DNA Double-Strand Break Repair. Carcinogenesis; 2010; 31, pp. 961-967. [DOI: https://dx.doi.org/10.1093/carcin/bgq069]
138. Metcalfe, K.; Lynch, H.T.; Ghadirian, P.; Tung, N.; Olivotto, I.; Warner, E.; Olopade, O.I.; Eisen, A.; Weber, B.; McLennan, J. et al. Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. J. Clin. Oncol.; 2016; 22, pp. 2328-2335. [DOI: https://dx.doi.org/10.1200/JCO.2004.04.033]
139. Welcsh, P.L.; King, M.C. BRCA1 and BRCA2 and the Genetics of Breast and Ovarian Cancer. Hum. Mol. Genet.; 2001; 10, pp. 705-713. [DOI: https://dx.doi.org/10.1093/hmg/10.7.705]
140. Arruabarrena-Aristorena, A.; Toska, E. Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. Front. Oncol.; 2022; 12, 924808. [DOI: https://dx.doi.org/10.3389/fonc.2022.924808]
141. Thang, N.X.; Yoo, S.; La, H.; Lee, H.; Park, C.; Park, K.S.; Hong, K. Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer. Biomedicines; 2022; 10, 748. [DOI: https://dx.doi.org/10.3390/biomedicines10040748] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35453496]
142. Garcia-Martinez, L.; Zhang, Y.; Nakata, Y.; Chan, H.L.; Morey, L. Epigenetic Mechanisms in Breast Cancer Therapy and Resistance. Nat. Commun.; 2021; 12, 1786. [DOI: https://dx.doi.org/10.1038/s41467-021-22024-3] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33741974]
143. Karsli-Ceppioglu, S.; Dagdemir, A.; Judes, G.; Ngollo, M.; Penault-Llorca, F.; Pajon, A.; Bignon, Y.J.; Bernard-Gallon, D. Epigenetic Mechanisms of Breast Cancer: An Update of the Current Knowledge. Epigenomics; 2014; 6, pp. 651-664. [DOI: https://dx.doi.org/10.2217/epi.14.59] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25531258]
144. Batra, R.N.; Lifshitz, A.; Vidakovic, A.T.; Chin, S.F.; Sati-Batra, A.; Sammut, S.J.; Provenzano, E.; Ali, H.R.; Dariush, A.; Bruna, A. et al. DNA Methylation Landscapes of 1538 Breast Cancers Reveal a Replication-Linked Clock, Epigenomic Instability and Cis-Regulation. Nat. Commun.; 2021; 12, 5406. [DOI: https://dx.doi.org/10.1038/s41467-021-25661-w] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34518533]
145. Chekhun, V.F.; Kulik, G.I.; Yurchenko, O.V.; Tryndyak, V.P.; Todor, I.N.; Luniv, L.S.; Tregubova, N.A.; Pryzimirska, T.V.; Montgomery, B.; Rusetskaya, N.V. et al. Role of DNA Hypomethylation in the Development of the Resistance to Doxorubicin in Human MCF-7 Breast Adenocarcinoma Cells. Cancer Lett.; 2006; 231, pp. 87-93. [DOI: https://dx.doi.org/10.1016/j.canlet.2005.01.038]
146. Luzhna, L.; Kovalchuk, O. Modulation of DNA Methylation Levels Sensitizes Doxorubicin-Resistant Breast Adenocarcinoma Cells to Radiation-Induced Apoptosis. Biochem. Biophys. Res. Commun.; 2010; 392, pp. 113-117. [DOI: https://dx.doi.org/10.1016/j.bbrc.2009.12.093]
147. Pakneshan, P.; Szyf, M.; Farias-Eisner, R.; Rabbani, S.A. Reversal of the Hypomethylation Status of Urokinase (UPA) Promoter Blocks Breast Cancer Growth and Metastasis. J. Biol. Chem.; 2004; 279, pp. 31735-31744. [DOI: https://dx.doi.org/10.1074/jbc.M401669200]
148. Phuong, N.T.T.; Kim, S.K.; Lim, S.C.; Kim, H.S.; Kim, T.H.; Lee, K.Y.; Ahn, S.-G.; Yoon, J.-H.; Kang, K.W. Role of PTEN Promoter Methylation in Tamoxifen-Resistant Breast Cancer Cells. Breast Cancer Res. Treat.; 2011; 130, pp. 73-83. [DOI: https://dx.doi.org/10.1007/s10549-010-1304-2]
149. Shen, J.; He, Y.; Li, S.; Chen, H. Crosstalk of Methylation and Tamoxifen in Breast Cancer (Review). Mol. Med. Rep.; 2024; 30, 180. [DOI: https://dx.doi.org/10.3892/mmr.2024.13304]
150. Zhang, J.; Zhou, C.; Jiang, H.; Liang, L.; Shi, W.; Zhang, Q.; Sun, P.; Xiang, R.; Wang, Y.; Yang, S. ZEB1 Induces ER-α Promoter Hypermethylation and Confers Antiestrogen Resistance in Breast Cancer. Cell Death Dis.; 2017; 8, e2732. [DOI: https://dx.doi.org/10.1038/cddis.2017.154]
151. Jiménez-Garduño, A.M.; Mendoza-Rodríguez, M.G.; Urrutia-Cabrera, D.; Domínguez-Robles, M.C.; Pérez-Yépez, E.A.; Ayala-Sumuano, J.T.; Meza, I. IL-1β Induced Methylation of the Estrogen Receptor ERα Gene Correlates with EMT and Chemoresistance in Breast Cancer Cells. Biochem. Biophys. Res. Commun.; 2017; 490, pp. 780-785. [DOI: https://dx.doi.org/10.1016/j.bbrc.2017.06.117] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28645612]
152. Kim, M.R.; Wu, M.J.; Zhang, Y.; Yang, J.Y.; Chang, C.J. TET2 Directs Mammary Luminal Cell Differentiation and Endocrine Response. Nat. Commun.; 2020; 11, 4642. [DOI: https://dx.doi.org/10.1038/s41467-020-18129-w] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32934200]
153. Li, J.; Liang, Y.; Zhou, S.; Chen, J.; Wu, C. UCHL1 Contributes to Insensitivity to Endocrine Therapy in Triple-Negative Breast Cancer by Deubiquitinating and Stabilizing KLF5. Breast Cancer Res.; 2024; 26, 44. [DOI: https://dx.doi.org/10.1186/s13058-024-01800-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38468288]
154. Stone, A.; Zotenko, E.; Locke, W.J.; Korbie, D.; Millar, E.K.A.; Pidsley, R.; Stirzaker, C.; Graham, P.; Trau, M.; Musgrove, E.A. et al. DNA Methylation of Oestrogen-Regulated Enhancers Defines Endocrine Sensitivity in Breast Cancer. Nat. Commun.; 2015; 6, 7758. [DOI: https://dx.doi.org/10.1038/ncomms8758] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26169690]
155. Zou, J.X.; Duan, Z.; Wang, J.; Sokolov, A.; Xu, J.; Chen, C.Z.; Li, J.J.; Chen, H.W. Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance. Mol. Cancer Res.; 2014; 12, pp. 539-549. [DOI: https://dx.doi.org/10.1158/1541-7786.MCR-13-0459]
156. Zhao, W.; Sun, M.; Li, S.; Chen, Z.; Geng, D. Transcription Factor ATF3 Mediates the Radioresistance of Breast Cancer. J. Cell Mol. Med.; 2018; 22, pp. 4664-4675. [DOI: https://dx.doi.org/10.1111/jcmm.13688]
157. Liu, X.; Gonzalez, G.; Dai, X.; Miao, W.; Yuan, J.; Huang, M.; Bade, D.; Li, L.; Sun, Y.; Wang, Y. Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an M6A-Based Epitranscriptomic Mechanism. Mol. Ther.; 2020; 28, 2593. [DOI: https://dx.doi.org/10.1016/j.ymthe.2020.09.007]
158. Wang, J.; Xie, S.; Yang, J.; Xiong, H.; Jia, Y.; Zhou, Y.; Chen, Y.; Ying, X.; Chen, C.; Ye, C. et al. The Long Noncoding RNA H19 Promotes Tamoxifen Resistance in Breast Cancer via Autophagy. J. Hematol. Oncol.; 2019; 12, 81. [DOI: https://dx.doi.org/10.1186/s13045-019-0747-0]
159. Phuong, N.T.T.; Kim, S.K.; Im, J.H.; Yang, J.W.; Choi, M.C.; Lim, S.C.; Lee, K.Y.; Kim, Y.M.; Yoon, J.H.; Kang, K.W. Induction of Methionine Adenosyltransferase 2A in Tamoxifen-Resistant Breast Cancer Cells. Oncotarget; 2016; 7, 13902. [DOI: https://dx.doi.org/10.18632/oncotarget.5298]
160. Xu, J.; Wu, D.; Wang, S.; Wang, Z. MAT2B Expression Correlates with Poor Prognosis in Triple-Negative Breast Cancer. Cancer Manag. Res.; 2019; 11, pp. 5501-5511. [DOI: https://dx.doi.org/10.2147/CMAR.S200716]
161. Wallace, H.M.; Duthie, J.; Evans, D.M.; Lamond, S.; Nicoll, K.M.; Heys, S.D. Alterations in Polyamine Catabolic Enzymes in Human Breast Cancer Tissue. Clin. Cancer Res.; 2000; 6, pp. 3657-3661. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10999758]
162. Akinyele, O.; Wallace, H.M. Characterising the Response of Human Breast Cancer Cells to Polyamine Modulation. Biomolecules; 2021; 11, 743. [DOI: https://dx.doi.org/10.3390/biom11050743] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34067619]
163. Kingsnorth, A.N.; Wallace, H.M.; Bundred, N.J.; Dixon, J.M.J. Polyamines in Breast Cancer. Br. J. Surg.; 2005; 71, pp. 352-356. [DOI: https://dx.doi.org/10.1002/bjs.1800710513] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/6722462]
164. Casero, R.A.; Murray Stewart, T.; Pegg, A.E. Polyamine Metabolism and Cancer: Treatments, Challenges and Opportunities. Nat. Rev. Cancer; 2018; 18, 681. [DOI: https://dx.doi.org/10.1038/s41568-018-0050-3]
165. Pegg, A.E.; Williams-Ashman, H.G. Phosphate-Stimulated Breakdown of 5’-Methylthioadenosine by Rat Ventral Prostate. Biochem. J.; 1969; 115, pp. 241-247. [DOI: https://dx.doi.org/10.1042/bj1150241]
166. Schmid, M.; Sen, M.; Rosenbach, M.D.; Carrera, C.J.; Friedman, H.; Carson, D.A. A Methylthioadenosine Phosphorylase (MTAP) Fusion Transcript Identifies a New Gene on Chromosome 9p21 That Is Frequently Deleted in Cancer. Oncogene; 2000; 19, pp. 5747-5754. [DOI: https://dx.doi.org/10.1038/sj.onc.1203942]
167. Zhang, Y.; Zhang, T.T.; Gao, L.; Tan, Y.N.; Li, Y.T.; Tan, X.Y.; Huang, T.X.; Li, H.H.; Bai, F.; Zou, C. et al. Downregulation of MTAP Promotes Tumor Growth and Metastasis by Regulating ODC Activity in Breast Cancer. Int. J. Biol. Sci.; 2022; 18, 3034. [DOI: https://dx.doi.org/10.7150/ijbs.67149]
168. Liao, R.; Chen, X.; Cao, Q.; Bai, L.; Ma, C.; Dai, Z.; Dong, C. AMD1 Promotes Breast Cancer Aggressiveness via a Spermidine-EIF5A Hypusination-TCF4 Axis. Breast Cancer Res.; 2024; 26, 70. [DOI: https://dx.doi.org/10.1186/s13058-024-01825-6]
169. Hill, W.; Lim, E.L.; Weeden, C.E.; Lee, C.; Augustine, M.; Chen, K.; Kuan, F.C.; Marongiu, F.; Evans, E.J.; Moore, D.A. et al. Lung Adenocarcinoma Promotion by Air Pollutants. Nature; 2023; 616, pp. 159-167. [DOI: https://dx.doi.org/10.1038/s41586-023-05874-3]
170. Petrovic, D.; Bodinier, B.; Dagnino, S.; Whitaker, M.; Karimi, M.; Campanella, G.; Haugdahl Nøst, T.; Polidoro, S.; Palli, D.; Krogh, V. et al. Epigenetic Mechanisms of Lung Carcinogenesis Involve Differentially Methylated CpG Sites beyond Those Associated with Smoking. Eur. J. Epidemiol.; 2022; 37, 629. [DOI: https://dx.doi.org/10.1007/s10654-022-00877-2]
171. Zhu, T.; Bao, X.; Chen, M.; Lin, R.; Zhuyan, J.; Zhen, T.; Xing, K.; Zhou, W.; Zhu, S. Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis. Front. Oncol.; 2020; 10, 585284. [DOI: https://dx.doi.org/10.3389/fonc.2020.585284] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33262947]
172. Kaufman, J.M.; Amann, J.M.; Park, K.; Arasada, R.R.; Li, H.; Shyr, Y.; Carbone, D.P. LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT. J. Thorac. Oncol.; 2014; 9, 794. [DOI: https://dx.doi.org/10.1097/JTO.0000000000000173]
173. Koenig, M.J.; Agana, B.A.; Kaufman, J.M.; Sharpnack, M.F.; Wang, W.Z.; Weigel, C.; Navarro, F.C.P.; Amann, J.M.; Cacciato, N.; Arasada, R.R. et al. STK11/LKB1 Loss of Function Is Associated with Global DNA Hypomethylation and S-Adenosyl-Methionine Depletion in Human Lung Adenocarcinoma. Cancer Res.; 2021; 81, pp. 4194-4204. [DOI: https://dx.doi.org/10.1158/0008-5472.CAN-20-3199] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34045189]
174. Ulanovskaya, O.A.; Zuhl, A.M.; Cravatt, B.F. NNMT Promotes Epigenetic Remodeling in Cancer by Creating a Metabolic Methylation Sink. Nat. Chem. Biol.; 2013; 9, 300. [DOI: https://dx.doi.org/10.1038/nchembio.1204] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23455543]
175. Tomida, M.; Mikami, I.; Takeuchi, S.; Nishimura, H.; Akiyama, H. Serum Levels of Nicotinamide N-Methyltransferase in Patients with Lung Cancer. J. Cancer Res. Clin. Oncol.; 2009; 135, pp. 1223-1229. [DOI: https://dx.doi.org/10.1007/s00432-009-0563-y] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19242722]
176. Wang, Z.; Yip, L.Y.; Lee, J.H.J.; Wu, Z.; Chew, H.Y.; Chong, P.K.W.; Teo, C.C.; Ang, H.Y.K.; Peh, K.L.E.; Yuan, J. et al. Methionine Is a Metabolic Dependency of Tumor-Initiating Cells. Nat. Med.; 2019; 25, pp. 825-837. [DOI: https://dx.doi.org/10.1038/s41591-019-0423-5]
177. Zhao, X.; Wang, L.; Lin, H.; Wang, J.; Fu, J.; Zhu, D.; Xu, W. Inhibition of MAT2A-Related Methionine Metabolism Enhances The Efficacy of Cisplatin on Cisplatin-Resistant Cells in Lung Cancer. Cell J. Yakhteh; 2022; 24, 204. [DOI: https://dx.doi.org/10.22074/CELLJ.2022.7907]
178. Liu, C.; Ren, Q.; Deng, J.; Wang, S.; Ren, L. C-MYC/METTL3/LINC01006 Positive Feedback Loop Promotes Migration, Invasion and Proliferation of Non-Small Cell Lung Cancer. Biomed. J.; 2024; 47, 100664. [DOI: https://dx.doi.org/10.1016/j.bj.2023.100664]
179. Xuan, Y.F.; Lu, S.; Ou, Y.J.; Bao, X.B.; Huan, X.J.; Song, S.S.; Miao, Z.H.; Wang, Y.Q. The Combination of Methionine Adenosyltransferase 2A Inhibitor and Methyltransferase like 3 Inhibitor Promotes Apoptosis of Non-Small Cell Lung Cancer Cells and Produces Synergistic Anti-Tumor Activity. Biochem. Biophys. Res. Commun.; 2024; 716, 150011. [DOI: https://dx.doi.org/10.1016/j.bbrc.2024.150011]
180. Ascenção, K.; Szabo, C. Emerging Roles of Cystathionine β-Synthase in Various Forms of Cancer. Redox Biol.; 2022; 53, 102331. [DOI: https://dx.doi.org/10.1016/j.redox.2022.102331]
181. Qiu, L.; Hu, L.; Wang, H.; Li, J.; Ruan, X.; Sun, B.; Zhi, J.; Zheng, X.; Gu, L.; Gao, M. et al. FATS Regulates Polyamine Biosynthesis by Promoting ODC Degradation in an ERβ-Dependent Manner in Non-Small-Cell Lung Cancer. Cell Death Dis.; 2020; 11, 839. [DOI: https://dx.doi.org/10.1038/s41419-020-03052-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33037185]
182. Basu, I.; Locker, J.; Cassera, M.B.; Belbin, T.J.; Merino, E.F.; Dong, X.; Hemeon, I.; Evans, G.B.; Guha, C.; Schramm, V.L. Growth and Metastases of Human Lung Cancer Are Inhibited in Mouse Xenografts by a Transition State Analogue of 5’-Methylthioadenosine Phosphorylase. J. Biol. Chem.; 2011; 286, pp. 4902-4911. [DOI: https://dx.doi.org/10.1074/jbc.M110.198374] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21135097]
183. Xu, Y.; Hong, Z.; Yu, S.; Huang, R.; Li, K.; Li, M.; Xie, S.; Zhu, L. Fresh Insights Into SLC25A26: Potential New Therapeutic Target for Cancers: A Review. Oncol. Rev.; 2024; 18, 1379323. [DOI: https://dx.doi.org/10.3389/or.2024.1379323] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38745827]
184. Ye, Q.; Singh, S.; Qian, P.R.; Guo, N.L. Immune-Omics Networks of Cd27, Pd1, and Pdl1 in Non-Small Cell Lung Cancer. Cancers; 2021; 13, 4296. [DOI: https://dx.doi.org/10.3390/cancers13174296] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34503105]
185. Winawer, S.J. Natural History of Colorectal Cancer. Am. J. Med.; 1999; 106, pp. 3-6. [DOI: https://dx.doi.org/10.1016/S0002-9343(98)00338-6]
186. Nazemalhosseini Mojarad, E.; Kuppen, P.J.; Aghdaei, H.A.; Zali, M.R. The CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Gastroenterol. Hepatol. Bed Bench; 2013; 6, pp. 120-128.
187. Advani, S.M.; Advani, P.; DeSantis, S.M.; Brown, D.; VonVille, H.M.; Lam, M.; Loree, J.M.; Sarshekeh, A.M.; Bressler, J.; Lopez, D.S. et al. Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-Analysis. Transl. Oncol.; 2018; 11, pp. 1188-1201. [DOI: https://dx.doi.org/10.1016/j.tranon.2018.07.008]
188. Ewing, I.; Hurley, J.J.; Josephides, E.; Millar, A. The Molecular Genetics of Colorectal Cancer. Frontline Gastroenterol.; 2014; 5, pp. 26-30. [DOI: https://dx.doi.org/10.1136/flgastro-2013-100329]
189. Helderman, N.C.; Andini, K.D.; van Leerdam, M.E.; van Hest, L.P.; Hoekman, D.R.; Ahadova, A.; Bajwa-ten Broeke, S.W.; Bosse, T.; van der Logt, E.M.J.; Imhann, F. et al. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome. J. Mol. Diagn.; 2024; 26, pp. 106-114. [DOI: https://dx.doi.org/10.1016/j.jmoldx.2023.10.005]
190. Levine, A.J.; Phipps, A.I.; Baron, J.A.; Buchanan, D.D.; Ahnen, D.J.; Cohen, S.A.; Lindor, N.M.; Newcomb, P.A.; Rosty, C.; Haile, R.W. et al. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. Cancer Epidemiol. Biomark. Prev.; 2016; 25, pp. 68-75. [DOI: https://dx.doi.org/10.1158/1055-9965.EPI-15-0935]
191. Suter, C.M.; Martin, D.I.; Ward, R.I. Hypomethylation of L1 Retrotransposons in Colorectal Cancer and Adjacent Normal Tissue. Int. J. Colorectal Dis.; 2004; 19, pp. 95-101. [DOI: https://dx.doi.org/10.1007/s00384-003-0539-3] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14534800]
192. Rodriguez, J.; Frigola, J.; Vendrell, E.; Risques, R.A.; Fraga, M.F.; Morales, C.; Moreno, V.; Esteller, M.; Capellà, G.; Ribas, M. et al. Chromosomal Instability Correlates with Genome-Wide DNA Demethylation in Human Primary Colorectal Cancers. Cancer Res.; 2006; 66, pp. 8462-8468. [DOI: https://dx.doi.org/10.1158/0008-5472.CAN-06-0293] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16951157]
193. Szigeti, K.A.; Kalmár, A.; Galamb, O.; Valcz, G.; Barták, B.K.; Nagy, Z.B.; Zsigrai, S.; Felletár, I.; Patai, Á.V.; Micsik, T. et al. Global DNA Hypomethylation of Colorectal Tumours Detected in Tissue and Liquid Biopsies May Be Related to Decreased Methyl-Donor Content. BMC Cancer; 2022; 22, 605. [DOI: https://dx.doi.org/10.1186/s12885-022-09659-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35655145]
194. Mima, K.; Nowak, J.A.; Qian, Z.R.; Cao, Y.; Song, M.; Masugi, Y.; Shi, Y.; da Silva, A.; Gu, M.; Li, W. et al. Tumor LINE-1 Methylation Level and Colorectal Cancer Location in Relation to Patient Survival. Oncotarget; 2016; 7, 55098. [DOI: https://dx.doi.org/10.18632/oncotarget.10398]
195. Antelo, M.; Balaguer, F.; Shia, J.; Shen, Y.; Hur, K.; Moreira, L.; Cuatrecasas, M.; Bujanda, L.; Giraldez, M.D.; Takahashi, M. et al. A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer. PLoS ONE; 2012; 7, e45357. [DOI: https://dx.doi.org/10.1371/journal.pone.0045357]
196. Alonso-Aperte, E.; González, M.P.; Póo-Prieto, R.; Varela-Moreiras, G. Folate Status and S-Adenosylmethionine/S-Adenosylhomocysteine Ratio in Colorectal Adenocarcinoma in Humans. Eur. J. Clin. Nutr.; 2007; 62, pp. 295-298. [DOI: https://dx.doi.org/10.1038/sj.ejcn.1602722]
197. Sibani, S.; Melnyk, S.; Pogribny, I.P.; Wang, W.; Hiou-Tim, F.; Deng, L.; Trasler, J.; Jill James, S.; Rozen, R. Studies of Methionine Cycle Intermediates (SAM, SAH), DNA Methylation and the Impact of Folate Deficiency on Tumor Numbers in Min Mice. Carcinogenesis; 2002; 23, pp. 61-65. [DOI: https://dx.doi.org/10.1093/carcin/23.1.61]
198. Luo, J.; Li, Y.N.; Wang, F.; Zhang, W.M.; Geng, X. S-Adenosylmethionine Inhibits the Growth of Cancer Cells by Reversing the Hypomethylation Status of c-Myc and H-Ras in Human Gastric Cancer and Colon Cancer. Int. J. Biol. Sci.; 2010; 6, pp. 784-795. [DOI: https://dx.doi.org/10.7150/ijbs.6.784]
199. Ito, K.; Ikeda, S.; Kojima, N.; Miura, M.; Shimizu-Saito, K.; Yamaguchi, I.; Katsuyama, I.; Sanada, K.; Iwai, T.; Senoo, H. et al. Correlation between the Expression of Methionine Adenosyltransferase and the Stages of Human Colorectal Carcinoma. Surg. Today; 2000; 30, pp. 706-710. [DOI: https://dx.doi.org/10.1007/s005950070081]
200. Chen, H.; Xia, M.; Lin, M.; Yang, H.; Kuhlenkamp, J.; Li, T.; Sodir, N.M.; Chen, Y.H.; Josef-Lenz, H.; Laird, P.W. et al. Role of Methionine Adenosyltransferase 2A and S-Adenosylmethionine in Mitogen-Induced Growth of Human Colon Cancer Cells. Gastroenterology; 2007; 133, pp. 207-218. [DOI: https://dx.doi.org/10.1053/j.gastro.2007.03.114]
201. Li, T.W.H.; Zhang, Q.; Oh, P.; Xia, M.; Chen, H.; Bemanian, S.; Lastra, N.; Circ, M.; Moyer, M.P.; Mato, J.M. et al. S-Adenosylmethionine and Methylthioadenosine Inhibit Cellular FLICE Inhibitory Protein Expression and Induce Apoptosis in Colon Cancer Cells. Mol. Pharmacol.; 2009; 76, 192. [DOI: https://dx.doi.org/10.1124/mol.108.054411] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19372210]
202. Tomasi, M.L.; Cossu, C.; Spissu, Y.; Floris, A.; Ryoo, M.; Iglesias-Ara, A.; Wang, Q.; Pandol, S.J.; Bhowmick, N.A.; Seki, E. et al. S-Adenosylmethionine and Methylthioadenosine Inhibit Cancer Metastasis by Targeting MicroRNA 34a/b-Methionine Adenosyltransferase 2A/2B Axis. Oncotarget; 2017; 8, pp. 78851-78869. [DOI: https://dx.doi.org/10.18632/oncotarget.20234] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29108270]
203. Borzacchiello, L.; Veglia Tranchese, R.; Grillo, R.; Arpino, R.; Mosca, L.; Cacciapuoti, G.; Porcelli, M. S-Adenosylmethionine Inhibits Colorectal Cancer Cell Migration through Mirna-Mediated Targeting of Notch Signaling Pathway. Int. J. Mol. Sci.; 2022; 23, 7673. [DOI: https://dx.doi.org/10.3390/ijms23147673] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35887021]
204. Phillips, C.M.; Zatarain, J.R.; Nicholls, M.E.; Porter, C.; Widen, S.G.; Thanki, K.; Johnson, P.; Jawad, M.U.; Moyer, M.P.; Randall, J.W. et al. Upregulation of Cystathionine-β-Synthase in Colonic Epithelia Reprograms Metabolism and Promotes Carcinogenesis. Cancer Res.; 2017; 77, pp. 5741-5754. [DOI: https://dx.doi.org/10.1158/0008-5472.CAN-16-3480]
205. Módis, K.; Coletta, C.; Asimakopoulou, A.; Szczesny, B.; Chao, C.; Papapetropoulos, A.; Hellmich, M.R.; Szabo, C. Effect of S-Adenosyl-l-Methionine (SAM), an Allosteric Activator of Cystathionine-β-Synthase (CBS) on Colorectal Cancer Cell Proliferation and Bioenergetics in Vitro. Nitric Oxide; 2014; 41, pp. 146-156. [DOI: https://dx.doi.org/10.1016/j.niox.2014.03.001]
206. Liskova, V.; Chovancova, B.; Babula, P.; Rezuchova, I.; Pavlov, K.P.; Matuskova, M.; Krizanova, O. Cystathionine β-Synthase Affects Organization of Cytoskeleton and Modulates Carcinogenesis in Colorectal Carcinoma Cells. Front. Oncol.; 2023; 13, 1178021. [DOI: https://dx.doi.org/10.3389/fonc.2023.1178021]
207. Zhao, L.Y.; Tong, D.D.; Xue, M.; Ma, H.L.; Liu, S.Y.; Yang, J.; Liu, Y.X.; Guo, B.; Ni, L.; Liu, L.Y. et al. MeCP2, a Target of MiR-638, Facilitates Gastric Cancer Cell Proliferation through Activation of the MEK1/2–ERK1/2 Signaling Pathway by Upregulating GIT1. Oncogenesis; 2017; 6, e368. [DOI: https://dx.doi.org/10.1038/oncsis.2017.60]
208. Zhao, L.; Liu, Y.; Tong, D.; Qin, Y.; Yang, J.; Xue, M.; Du, N.; Liu, L.; Guo, B.; Hou, N. et al. MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways. EBioMedicine; 2017; 16, pp. 87-100. [DOI: https://dx.doi.org/10.1016/j.ebiom.2017.01.021]
209. Tong, D.; Zhang, J.; Wang, X.; Li, Q.; Liu, L.; Lu, A.; Guo, B.; Yang, J.; Ni, L.; Qin, H. et al. MiR-22, Regulated by MeCP2, Suppresses Gastric Cancer Cell Proliferation by Inducing a Deficiency in Endogenous S-Adenosylmethionine. Oncogenesis; 2020; 9, 99. [DOI: https://dx.doi.org/10.1038/s41389-020-00281-z]
210. Ma, M.; Kong, P.; Huang, Y.; Wang, J.; Liu, X.; Hu, Y.; Chen, X.; Du, C.; Yang, H. Activation of MAT2A-ACSL3 Pathway Protects Cells from Ferroptosis in Gastric Cancer. Free Radic. Biol. Med.; 2022; 181, pp. 288-299. [DOI: https://dx.doi.org/10.1016/j.freeradbiomed.2022.02.015]
211. Zhang, Y.; Yang, H.; Zhao, J.; Wan, P.; Hu, Y.; Lv, K.; Hu, Y.; Yang, X.; Ma, M. Activation of MAT2A-RIP1 Signaling Axis Reprograms Monocytes in Gastric Cancer. J. Immunother. Cancer; 2021; 9, e001364. [DOI: https://dx.doi.org/10.1136/jitc-2020-001364] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33593829]
212. Shukeir, N.; Pakneshan, P.; Chen, G.; Szyf, M.; Rabbani, S.A. Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In Vitro and In Vivo. Cancer Res.; 2006; 66, pp. 9202-9210. [DOI: https://dx.doi.org/10.1158/0008-5472.CAN-06-1954] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16982764]
213. Mathes, A.; Duman, M.B.; Neumann, A.; Dobreva, G.; Schmidt, T. S-Adenosylmethionine Treatment Affects Histone Methylation in Prostate Cancer Cells. Gene; 2024; 893, 147915. [DOI: https://dx.doi.org/10.1016/j.gene.2023.147915] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37866662]
214. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.; Jeter, C.; Honorio, S. et al. Identification of MiR-34a as a Potent Inhibitor of Prostate Cancer Progenitor Cells and Metastasis by Directly Repressing CD44. Nat. Med.; 2011; 17, 211. [DOI: https://dx.doi.org/10.1038/nm.2284]
215. Tang, Y.; Tang, Y.; Cheng, Y.S. MiR-34a Inhibits Pancreatic Cancer Progression through Snail1-Mediated Epithelial–Mesenchymal Transition and the Notch Signaling Pathway. Sci. Rep.; 2017; 7, 38232. [DOI: https://dx.doi.org/10.1038/srep38232]
216. Shukla-Dave, A.; Castillo-Martin, M.; Chen, M.; Lobo, J.; Gladoun, N.; Collazo-Lorduy, A.; Khan, F.M.; Ponomarev, V.; Yi, Z.; Zhang, W. et al. Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. Am. J. Pathol.; 2016; 186, pp. 3131-3145. [DOI: https://dx.doi.org/10.1016/j.ajpath.2016.08.021]
217. Zabala-Letona, A.; Arruabarrena-Aristorena, A.; Martín-Martín, N.; Fernandez-Ruiz, S.; Sutherland, J.D.; Clasquin, M.; Tomas-Cortazar, J.; Jimenez, J.; Torres, I.; Quang, P. et al. MTORC1-Dependent AMD1 Regulation Sustains Polyamine Metabolism in Prostate Cancer. Nature; 2017; 547, pp. 109-113. [DOI: https://dx.doi.org/10.1038/nature22964]
218. Bistulfi, G.; Affronti, H.C.; Foster, B.A.; Karasik, E.; Gillard, B.; Morrison, C.; Mohler, J.; Phillips, J.G.; Smiraglia, D.J. The Essential Role of Methylthioadenosine Phosphorylase in Prostate Cancer. Oncotarget; 2016; 7, 14380. [DOI: https://dx.doi.org/10.18632/oncotarget.7486]
219. Barve, A.; Vega, A.; Shah, P.P.; Ghare, S.; Casson, L.; Wunderlich, M.; Siskind, L.J.; Beverly, L.J. Perturbation of Methionine/S-Adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia. Cells; 2019; 8, 1322. [DOI: https://dx.doi.org/10.3390/cells8111322]
220. Harachi, M.; Masui, K.; Honda, H.; Muragaki, Y.; Kawamata, T.; Cavenee, W.K.; Mischel, P.S.; Shibata, N. Dual Regulation of Histone Methylation by MTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. Mol. Cancer Res.; 2020; 18, pp. 1142-1152. [DOI: https://dx.doi.org/10.1158/1541-7786.MCR-20-0024]
221. Mosca, L.; Pagano, C.; Tranchese, R.V.; Grillo, R.; Cadoni, F.; Navarra, G.; Coppola, L.; Pagano, M.; Mele, L.; Cacciapuoti, G. et al. Antitumoral Activity of the Universal Methyl Donor S-Adenosylmethionine in Glioblastoma Cells. Molecules; 2024; 29, 1708. [DOI: https://dx.doi.org/10.3390/molecules29081708] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38675528]
222. Liteplo, R.G.; Munro, S. DNA Methylating Capacity in Metastatic Variants of a Human Melanoma Cell Line. Cancer Lett.; 1988; 41, pp. 191-198. [DOI: https://dx.doi.org/10.1016/0304-3835(88)90115-2] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3401842]
223. Liteplo, R.G. Altered Methionine Metabolism in Metastatic Variants of a Human Melanoma Cell Line. Cancer Lett.; 1989; 44, pp. 23-31. [DOI: https://dx.doi.org/10.1016/0304-3835(89)90103-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2917339]
224. Zhou, D.; Shi, H.; Mu, W.; Zhang, B.; Meng, T.; Zhang, S. Potential Role of S-Adenosylmethionine in Osteosarcoma Development. Onco Targets Ther.; 2016; 9, 3653. [DOI: https://dx.doi.org/10.2147/OTT.S101408]
225. Mehdi, A.; Attias, M.; Arakelian, A.; Szyf, M.; Piccirillo, C.A.; Rabbani, S.A. S-Adenosylmethionine Blocks Tumorigenesis and with Immune Checkpoint Inhibitor Enhances Anti-Cancer Efficacy against BRAF Mutant and Wildtype Melanomas. Neoplasia; 2023; 36, 100874. [DOI: https://dx.doi.org/10.1016/j.neo.2022.100874]
226. Ilisso, C.P.; Sapio, L.; Delle Cave, D.; Illiano, M.; Spina, A.; Cacciapuoti, G.; Naviglio, S.; Porcelli, M. S-Adenosylmethionine Affects ERK1/2 and Stat3 Pathways and Induces Apotosis in Osteosarcoma Cells. J. Cell Physiol.; 2016; 231, pp. 428-435. [DOI: https://dx.doi.org/10.1002/jcp.25089]
227. Parashar, S.; Cheishvili, D.; Arakelian, A.; Hussain, Z.; Tanvir, I.; Khan, H.A.; Szyf, M.; Rabbani, S.A. S-Adenosylmethionine Blocks Osteosarcoma Cells Proliferation and Invasion in Vitro and Tumor Metastasis in Vivo: Therapeutic and Diagnostic Clinical Applications. Cancer Med.; 2015; 4, pp. 732-744. [DOI: https://dx.doi.org/10.1002/cam4.386]
228. Ye, F.; Chen, E.R.; Nilsen, T.W. Kaposi’s Sarcoma-Associated Herpesvirus Utilizes and Manipulates RNA N 6-Adenosine Methylation to Promote Lytic Replication. J. Virol.; 2017; 91, e00466-17. [DOI: https://dx.doi.org/10.1128/JVI.00466-17]
229. Zhang, X.; Meng, W.; Feng, J.; Gao, X.; Qin, C.; Feng, P.; Huang, Y.; Gao, S.J. METTL16 Controls Kaposi’s Sarcoma-Associated Herpesvirus Replication by Regulating S-Adenosylmethionine Cycle. Cell Death Dis.; 2023; 14, 591. [DOI: https://dx.doi.org/10.1038/s41419-023-06121-3]
230. Pozzi, V.; Molinelli, E.; Campagna, R.; Serritelli, E.N.; Cecati, M.; De Simoni, E.; Sartini, D.; Goteri, G.; Martin, N.I.; van Haren, M.J. et al. Knockdown of Nicotinamide N-Methyltransferase Suppresses Proliferation, Migration, and Chemoresistance of Merkel Cell Carcinoma Cells in Vitro. Hum. Cell; 2024; 37, pp. 729-738. [DOI: https://dx.doi.org/10.1007/s13577-024-01047-0]
231. Harmankaya, İ.; Akar, S.; Uğraş, S.; Güler, A.H.; Ezveci, H.; Aydoğdu, M.; Çelik, Ç. Nicotinamide N-Methyltransferase Overexpression May Be Associated with Poor Prognosis in Ovarian Cancer. J. Obstet. Gynaecol.; 2021; 41, pp. 248-253. [DOI: https://dx.doi.org/10.1080/01443615.2020.1732891] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32285726]
232. Sartini, D.; Santarelli, A.; Rossi, V.; Goteri, G.; Rubini, C.; Ciavarella, D.; Lo Muzio, L.; Emanuelli, M. Nicotinamide N-Methyltransferase Upregulation Inversely Correlates with Lymph Node Metastasis in Oral Squamous Cell Carcinoma. Mol. Med.; 2007; 13, 415. [DOI: https://dx.doi.org/10.2119/2007-00035.Sartini] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17622326]
233. Neelakantan, H.; Wang, H.Y.; Vance, V.; Hommel, J.D.; McHardy, S.F.; Watowich, S.J. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J. Med. Chem.; 2017; 60, pp. 5015-5028. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.7b00389] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28548833]
234. Kannt, A.; Rajagopal, S.; Kadnur, S.V.; Suresh, J.; Bhamidipati, R.K.; Swaminathan, S.; Hallur, M.S.; Kristam, R.; Elvert, R.; Czech, J. et al. A Small Molecule Inhibitor of Nicotinamide N-Methyltransferase for the Treatment of Metabolic Disorders. Sci. Rep.; 2018; 8, 3660. [DOI: https://dx.doi.org/10.1038/s41598-018-22081-7]
235. Lee, H.Y.; Suciu, R.M.; Horning, B.D.; Vinogradova, E.V.; Ulanovskaya, O.A.; Cravatt, B.F. Covalent Inhibitors of Nicotinamide N-Methyltransferase (NNMT) Provide Evidence for Target Engagement Challenges in Situ. Bioorg. Med. Chem. Lett.; 2018; 28, pp. 2682-2687. [DOI: https://dx.doi.org/10.1016/j.bmcl.2018.04.017]
236. Babault, N.; Allali-Hassani, A.; Li, F.; Fan, J.; Yue, A.; Ju, K.; Liu, F.; Vedadi, M.; Liu, J.; Jin, J. Discovery of Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT). J. Med. Chem.; 2018; 61, pp. 1541-1551. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.7b01422]
237. Wang, Y.; Muylaert, C.; Wyns, A.; Vlummens, P.; De Veirman, K.; Vanderkerken, K.; Zaal, E.; Berkers, C.; Moreaux, J.; De Bruyne, E. et al. S-Adenosylmethionine Biosynthesis Is a Targetable Metabolic Vulnerability in Multiple Myeloma. Haematologica; 2023; 109, 256. [DOI: https://dx.doi.org/10.3324/haematol.2023.282866]
238. Attia, R.R.; Gardner, L.A.; Mahrous, E.; Taxman, D.J.; LeGros, L.; Rowe, S.; Ting, J.P.-Y.; Geller, A.; Kotb, M. Selective Targeting of Leukemic Cell Growth in Vivo and in Vitro Using a Gene Silencing Approach to Diminish S-Adenosylmethionine Synthesis. J. Biol. Chem.; 2008; 283, pp. 30788-30795. [DOI: https://dx.doi.org/10.1074/jbc.M804159200]
239. Frau, M.; Tomasi, M.L.; Simile, M.M.; Demartis, M.I.; Salis, F.; Latte, G.; Calvisi, D.F.; Seddaiu, M.A.; Daino, L.; Feo, C.F. et al. Role of Transcriptional and Posttranscriptional Regulation of Methionine Adenosyltransferases in Liver Cancer Progression. Hepatology; 2012; 56, pp. 165-175. [DOI: https://dx.doi.org/10.1002/hep.25643]
240. Liu, Q.; Chen, J.; Liu, L.; Zhang, J.; Wang, D.; Ma, L.; He, Y.; Liu, Y.; Liu, Z.; Wu, J. The X Protein of Hepatitis B Virus Inhibits Apoptosis in Hepatoma Cells through Enhancing the Methionine Adenosyltransferase 2A Gene Expression and Reducing S-Adenosylmethionine Production. J. Biol. Chem.; 2011; 286, pp. 17168-17180. [DOI: https://dx.doi.org/10.1074/jbc.M110.167783]
241. Sadek, K.M.; Lebda, M.A.; Nasr, N.E.; Nasr, S.M.; EL-Sayed, Y. Role of LncRNAs as Prognostic Markers of Hepatic Cancer and Potential Therapeutic Targeting by S-Adenosylmethionine via Inhibiting PI3K/Akt Signaling Pathways. Environ. Sci. Pollut. Res. Int.; 2018; 25, pp. 20057-20070. [DOI: https://dx.doi.org/10.1007/s11356-018-2179-8]
242. Greenberg, A.K.; Rimal, B.; Felner, K.; Zafar, S.; Hung, J.; Eylers, E.; Phalan, B.; Zhang, M.; Goldberg, J.D.; Crawford, B. et al. S-Adenosylmethionine as a Biomarker for the Early Detection of Lung Cancer. Chest; 2007; 132, 1247. [DOI: https://dx.doi.org/10.1378/chest.07-0622] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17934114]
243. Fatemi, N.; Tierling, S.; Es, H.A.; Varkiani, M.; Mojarad, E.N.; Aghdaei, H.A.; Walter, J.; Totonchi, M. DNA Methylation Biomarkers in Colorectal Cancer: Clinical Applications for Precision Medicine. Int. J. Cancer; 2022; 151, pp. 2068-2081. [DOI: https://dx.doi.org/10.1002/ijc.34186] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35730647]
244. Pascale, R.M.; Simile, M.M.; Miglio, M.R.D.; Nufris, A.; Daino, L.; Seddaiu, M.A.; Rao, P.M.; Rajalakshmi, S.; Sarma, D.S.R.; Feo, F. Chemoprevention by S-Adenosyl-L-Methionine of Rat Liver Carcinogenesis Initiated by 1,2-Dimethylhydrazine and Promoted by Orotic Acid. Carcinogenesis; 1995; 16, pp. 427-430. [DOI: https://dx.doi.org/10.1093/carcin/16.2.427] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7859377]
245. Pascale, R.; Simile, M.M.; Ruggiu, M.E.; Seddaiu, M.A.; Satta, G.; Sequenza, M.J.; Daino, L.; Vannini, M.G.; Lai, P.; Feo, F. Reversal by 5-Azacytidine of the S-Adenosyl-L-Methionine-Induced Inhibition of the Development of Putative Preneoplastic Foci in Rat Liver Carcinogenesis. Cancer Lett.; 1991; 56, pp. 259-265. [DOI: https://dx.doi.org/10.1016/0304-3835(91)90011-6]
246. Feo, F.; Frau, M.; Feo, C.F.; Pascale, R.M. New Insights on the Role of Epigenetic Alterations in Hepatocellular Carcinoma. J. Hepatocell. Carcinoma; 2014; 1, pp. 65-83. [DOI: https://dx.doi.org/10.2147/JHC.S44506]
247. Stoyanov, E.; Mizrahi, L.; Olam, D.; Schnitzer-Perlman, T.; Galun, E.; Goldenberg, D.S.; Stoyanov, E.; Mizrahi, L.; Olam, D.; Schnitzer-Perlman, T. et al. Tumor-Suppressive Effect of S-Adenosylmethionine Supplementation in a Murine Model of Inflammation-Mediated Hepatocarcinogenesis Is Dependent on Treatment Longevity. Oncotarget; 2017; 8, pp. 104772-104784. [DOI: https://dx.doi.org/10.18632/oncotarget.18300]
248. Yan, L.; Liang, X.; Huang, H.; Zhang, G.; Liu, T.; Zhang, J.; Chen, Z.; Zhang, Z.; Chen, Y. S-Adenosylmethionine Affects Cell Cycle Pathways and Suppresses Proliferation in Liver Cells. J. Cancer; 2019; 10, pp. 4368-4379. [DOI: https://dx.doi.org/10.7150/jca.25422]
249. Morgan, T.R.; Osann, K.; Bottiglieri, T.; Pimstone, N.; Hoefs, J.C.; Hu, K.Q.; Hassanein, T.; Boyer, T.D.; Kong, L.; Chen, W.P. et al. A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prev. Res.; 2015; 8, pp. 864-872. [DOI: https://dx.doi.org/10.1158/1940-6207.CAPR-15-0029]
250. Li, J.; Ramani, K.; Sun, Z.; Zee, C.; Grant, E.G.; Yang, H.; Xia, M.; Oh, P.; Ko, K.; Mato, J.M. et al. Forced Expression of Methionine Adenosyltransferase 1A in Human Hepatoma Cells Suppresses in Vivo Tumorigenicity in Mice. Am. J. Pathol.; 2010; 176, pp. 2456-2466. [DOI: https://dx.doi.org/10.2353/ajpath.2010.090810]
251. Ilisso, C.P.; Delle Cave, D.; Mosca, L.; Pagano, M.; Coppola, A.; Mele, L.; Caraglia, M.; Cacciapuoti, G.; Porcelli, M. S-Adenosylmethionine Regulates Apoptosis and Autophagy in MCF-7 Breast Cancer Cells through the Modulation of Specific MicroRNAs. Cancer Cell Int.; 2018; 18, 197. [DOI: https://dx.doi.org/10.1186/s12935-018-0697-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30533999]
252. Delle Cave, D.; Ilisso, C.P.; Mosca, L.; Pagano, M.; Martino, E.; Porcelli, M.; Cacciapuoti, G. The Anticancer Effects of S-Adenosylmethionine on Breast Cancer Cells. JSM Chem.; 2018; 5, pp. 1049-1056.
253. Chik, F.; Machnes, Z.; Szyf, M. Synergistic Anti-Breast Cancer Effect of a Combined Treatment with the Methyl Donor S-Adenosyl Methionine and the DNA Methylation Inhibitor 5-Aza-2’-Deoxycytidine. Carcinogenesis; 2014; 35, pp. 138-144. [DOI: https://dx.doi.org/10.1093/carcin/bgt284]
254. Mahmood, N.; Arakelian, A.; Cheishvili, D.; Szyf, M.; Rabbani, S.A. S-Adenosylmethionine in Combination with Decitabine Shows Enhanced Anti-Cancer Effects in Repressing Breast Cancer Growth and Metastasis. J. Cell. Mol. Med.; 2020; 24, pp. 10322-10337. [DOI: https://dx.doi.org/10.1111/jcmm.15642] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32720467]
255. Ilisso, C.P.; Castellano, M.; Zappavigna, S.; Lombardi, A.; Vitale, G.; Dicitore, A.; Cacciapuoti, G.; Caraglia, M.; Porcelli, M. The Methyl Donor S-Adenosylmethionine Potentiates Doxorubicin Effects on Apoptosis of Hormone-Dependent Breast Cancer Cell Lines. Endocrine; 2015; 50, pp. 212-222. [DOI: https://dx.doi.org/10.1007/s12020-014-0484-7]
256. Cave, D.D.; Desiderio, V.; Mosca, L.; Ilisso, C.P.; Mele, L.; Caraglia, M.; Cacciapuoti, G.; Porcelli, M. S-Adenosylmethionine-Mediated Apoptosis Is Potentiated by Autophagy Inhibition Induced by Chloroquine in Human Breast Cancer Cells. J. Cell. Physiol.; 2018; 233, pp. 1370-1383. [DOI: https://dx.doi.org/10.1002/jcp.26015]
257. Mosca, L.; Pagano, M.; Ilisso, C.P.; Cave, D.D.; Desiderio, V.; Mele, L.; Caraglia, M.; Cacciapuoti, G.; Porcelli, M. AdoMet Triggers Apoptosis in Head and Neck Squamous Cancer by Inducing ER Stress and Potentiates Cell Sensitivity to Cisplatin. J. Cell. Physiol.; 2019; 234, pp. 13277-13291. [DOI: https://dx.doi.org/10.1002/jcp.28000]
258. Mosca, L.; Minopoli, M.; Pagano, M.; Vitiello, F.; Carriero, M.; Cacciapuoti, G.; Porcelli, M. Effects of S-adenosyl-L-methionine on the Invasion and Migration of Head and Neck Squamous Cancer Cells and Analysis of the Underlying Mechanisms. Int. J. Oncol.; 2020; 56, pp. 1212-1224. [DOI: https://dx.doi.org/10.3892/ijo.2020.5011]
259. Bedard, G.T.; Gilaj, N.; Peregrina, K.; Brew, I.; Tosti, E.; Shaffer, K.; Tyler, P.C.; Edelmann, W.; Augenlicht, L.H.; Schramm, V.L. Combined Inhibition of MTAP and MAT2a Mimics Synthetic Lethality in Tumor Models via PRMT5 Inhibition. J. Biol. Chem.; 2024; 300, 105492. [DOI: https://dx.doi.org/10.1016/j.jbc.2023.105492]
260. Mosca, L.; Pagano, M.; Pecoraro, A.; Borzacchiello, L.; Mele, L.; Cacciapuoti, G.; Porcelli, M.; Russo, G.; Russo, A. S-Adenosyl-l-Methionine Overcomes UL3-Mediated Drug Resistance in P53 Deleted Colon Cancer Cells. Int. J. Mol. Sci.; 2020; 22, 103. [DOI: https://dx.doi.org/10.3390/ijms22010103]
261. Zhao, Y.; Li, J.S.; Guo, M.Z.; Feng, B.S.; Zhang, J.P. Inhibitory Effect of S-Adenosylmethionine on the Growth of Human Gastric Cancer Cells in Vivo and in Vitro. Chin. J. Cancer; 2010; 29, pp. 752-760. [DOI: https://dx.doi.org/10.5732/cjc.010.10046] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20663323]
262. Schmidt, T. S-Adenosylmethionine Affects ERK1/2 and STAT3 Pathway in Androgen-Independent Prostate Cancer Cells. Mol. Biol. Rep.; 2022; 49, pp. 4805-4817. [DOI: https://dx.doi.org/10.1007/s11033-022-07331-2] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35303200]
263. Liu, M.; Mobet, Y.; Shen, H. S-Adenosylmethionine Inhibits the Proliferation of Retinoblastoma Cell Y79, Induces Apoptosis and Cell Cycle Arrest of Y79 Cells by Inhibiting the Wnt2/β-Catenin Pathway. Arch. Immunol. Ther. Exp.; 2024; 72, 20. [DOI: https://dx.doi.org/10.2478/aite-2024-0020]
264. Santini, D.; Vincenzi, B.; Massacesi, C.; Picardi, A.; Gentilucci, U.V.; Esposito, V.; Liuzzi, G.; La Cesa, A.; Rocci, L.; Marcucci, F. et al. S-Adenosylmethionine (AdoMet) Supplementation for Treatment of Chemotherapy-Induced Liver Injury. Anticancer Res.; 2003; 23, pp. 5173-5179. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14981985]
265. Vincenzi, B.; Santini, D.; Frezza, A.M.; Berti, P.; Vespasiani, U.; Picardi, A.; Tonini, G. The Role of S-Adenosyl Methionine in Preventing FOLFOX-Induced Liver Toxicity: A Retrospective Analysis in Patients Affected by Resected Colorectal Cancer Treated with Adjuvant FOLFOX Regimen. Expert Opin. Drug Saf.; 2011; 10, pp. 345-349. [DOI: https://dx.doi.org/10.1517/14740338.2011.562888]
266. Onorato, A.; Napolitano, A.; Spoto, S.; Incorvaia, L.; Russo, A.; Santini, D.; Tonini, G.; Vincenzi, B. S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens. Chemotherapy; 2021; 66, pp. 161-168. [DOI: https://dx.doi.org/10.1159/000517376]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Simple Summary
S-adenosylmethionine (SAMe) is a key molecule involved in cellular methylation and metabolic processes. It plays a crucial role in DNA, RNA and protein methylation, as well as in pathways like polyamine synthesis and transsulfuration. Dysregulation of SAMe metabolism is linked to various cancers, where its depletion leads to genomic instability, abnormal gene expression and tumor progression. Studies suggest SAMe could be a useful cancer biomarker and may enhance treatment by restoring methylation balance, reducing oxidative damage and protecting cells from chemotherapy effects. Targeting SAMe-related pathways, including combination with anticancer drugs, could offer new therapeutic options. Despite its potential, clinical applications remain challenging due to variability in response, poor bioavailability and the complexity of SAMe’s effects across different cancer types. Future research should focus on improving SAMe delivery, identifying biomarkers for patient-specific treatments and integrating SAMe with existing therapies. With further clinical validation, SAMe could become a valuable tool in personalized cancer treatment, helping to improve outcomes and expand therapeutic options.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain;
2 Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain;
3 Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA;